

# ***Bibliografia***

**Abrahamson EE, Leak RK and Moore RY.** The suprachiasmatic nucleus projects to posterior hypothalamic arousal system. *Neuroreport* 12:435-440, (2001b).

**Adkins C. E., Pillai G. V., Kerby J., Bonnert T.P., Haldon C., McKernan R.M., Gonzalez J. E., Oades K., Whiting P. J., and Simpson P. B. (2001).**  $\alpha_4\beta_3\delta$  GABA<sub>A</sub> receptors characterized by fluorescence resonance energy transfer-derived measurements of membrane potential. *J Biol Chem* 276:38934-38939.

**Akbari E., Naghdi N., Motamedi F., (2006).** Functional inactivation of orexin 1 receptors in CA1 region impairs acquisition, consolidation and retrieval in Morris water maze task. *Behav Brain Res; 173:47–52.*

**Alam N., Kumar S., Bar T., Suntsova N., Methippara M. M., Szymusiak R., McGinty D., (2005).** GABA-mediated control of hypocretin but not melanin-concentrating hormone-immunoreactive neurones during sleep in rats. *J Physiol* 563:569-582.

**Albert P. R., Lemonde S. (2004).** 5-HT<sub>1A</sub> receptors, gene repression, and depression: guilt by association. *Neuroscientist* 10:575–593.

**Alberto C. O., Trask R. B., Quinlan M. E. and Hirasawa M., (2006).** Bidirectional dopaminergic modulation of excitatory synaptic transmission in orexin neurons. *J. Neurosci.* 26:10043–1005.

**Aldredge B. (2010).** Pathogenic involvement of neuropeptides in anxiety and depression. *Neuropeptides* 44(3):215-24.

**Allison C., Pratt J. A. (2006).** Differential effects of two chronic diazepam treatment regimes on withdrawal anxiety and AMPA receptor characteristics. *Neuropsychopharmacology* 31(3):602-19.

**Alonso J., Lepine J. P. (2007).** Overview of key data from the European Study of Epidemiology of Mental Disorders (ESEMeD). *J Clin Psychiatry* 68:3–9.

**Alvarez C. E., Sutcliffe J. G., (2002).** Hypocretin is an early member of the incretin gene family. *Neuroscience Letters* 324:169-172.

**Amico J. A., Cai H. M., Vollmer R. R. (2008).** Corticosterone release in oxytocin gene deletion mice following exposure to psychogenic versus nonpsychogenic stress. *Neurosci Lett* 442,262–266.

**Ammoun S., Lindholm D., Wootz H., Akerman K. E., Kukkonen J. P. (2006).** G-protein-coupled OX1 orexin/hcrtr-1 hypocretin receptors induce caspase-dependent and-independent cell death through p38 mitogen-/stress- activated protein-kinase. *J. Biol. Chem* 281:834-841.

**Amorapanth P., LeDoux J. E., Nader K. (2000).** Different lateral amygdala outputs mediate reactions and actions elicited by a fear-arousing stimulus. *Nat Neurosci* 3:74–79.

**Anand A., Shekhar A. (2003)** Brain imaging studies in mood and anxiety disorders: special emphasis on the amygdala. *Ann N Y Acad Sci* 985:370-88.

**Andrew Novick., Irene Yaroslavky., Shanaz Tejani-Butt., (2008).** Strain differences in the expression of dopamine D1 receptors in Wistar-Kyoto (WKY) and Wistar rats. *Department of Pharmaceutical Sciences, University of Sciences in Philadelphia, 600 S. 43rd St., Philadelphia, PA 19104, United States.*

**Antunes V. R., Brailou G. C., Kwok E. H., Scruggs P., Dunn J. (2001).** Orexins/hypocretins excite rat sympathetic preganglionic neurons in vivo and in vitro. *Am J Physiol Regul Integr Comp Physiol* 281:R1801-R1807.

**Arai M., Assil I. Q., Abou-Samra A. B. (2001).** Characterization of three corticotropin-releasing factor receptors in catfish: a novel third receptor is predominantly expressed in pituitary and urophysis. *Endocrinology* 142,446–454.

**Arendh T. H., (2003).** Synaptic plasticity and cell cycle activation in neurons are alternative effector pathways: the Dr. Jekyll and Mr. Hyde concept of Alzheimer's disease or the yin and yang of neuroplasticity. *Prog Neurobiol* 7:83-248.

**Arendt T. H., (2004).** Neurodegeneration and plasticity. *Int J Devl Neurosci* 22:507-514.

**Aroniadou-Anderjaska V., Qashu F., Braga M. F. (2007).** Mechanisms regulating GABAergic inhibitory transmission in the basolateral amygdala: implications for epilepsy and anxiety disorders. *Amino Acids* 32(3):305-15.

**Atack J. R. (2005).** The benzodiazepine binding site of GABA(A) receptors as a target for the development of novel anxiolytics. *Expert Opin Investig Drug* 14:601–618.

**Aton S. J., Seibt J., Dumoulin M., Jha S. K., Steinmetz N., Coleman T., Naidoo N. Frank M. G. (2009).** Mechanisms of sleep-dependent consolidation of cortical plasticity. *Neuron* 61,454–466.

**Auclair N., Otani S., Soubrie P., Crepel F. (2000).** Cannabinoids modulate synaptic alteration of the expression of the hypocretin (orexin) gene by 2-deoxyglucose in the rat lateral hypothalamic area. *Neuroreport* 11:531-533.

**Avolio E., Alò R., Carelli A., (2010).** Amigdalor Orexinergic-GABAergic interactions regulate anxiety behaviors of the Syrian golden hamster. *Behav Brain Res* (In press).

**Azad S. C., Eder M., Marsicano G., Lutz B., Zieglgansberger W., Rammes G. (2003).** Activation of cannabinoid receptor type 1 decreases glutamatergic and GABAergic synaptic transmission in the lateral amygdala of the mouse. *Learn Mem* 10:116 –128.

**Bacchi F., Mathé A. A., Jiménez P., Stasi L., Arban R., Gerrard P., Caberlotto L. (2006).** Anxiolytic-like effect of the selective neuropeptide Y Y2 receptor antagonist BIIE0246 in the elevated plus-maze. *Peptides* 27,3202–3207.

**Bacci A, Coco S, Pravettoni E, Schenk U, Armano S, Frassoni C, Verderio C, De Camilli P, Matteoli M.** Chronic blockade of glutamate receptors enhances presynaptic release and downregulates the interaction between synaptophysin-synaptobrevin-vesicle-associated membrane protein 2. *J Neurosci* 21:6588-6596, (2001).

**Balazs R., Bridges R. J., Cotman., (2006).** Excitatory aminoacid transmission in Health and Disease-. *Oxford University Press, New York NY.*

**Balcita-Pedicino J. J., Sesack S. R., (2007).** Orexin axons in the rat ventral tegmental area synapse infrequently onto dopamine and gamma-aminobutyric acid neurons. *J Comp Neurol* 503: 668-84, (2007).

- Baldwin A. E., Holahan M. R., Sadeghian K., Kelley A. E., (2000).** N-methyl-Daspartate receptor-dependent plasticity within a distributed corticostriatal network mediates appetitive instrumental learning. *Behav Neurosci.*, 114: 1-15.
- Baldwin A. E., Sadeghian K., (2002).** Appetitive instrumental learning requires coincident activation of NMDA and dopamine D1 receptors within the medial prefrontal cortex. *J Neurosci*; 22:1063–71.
- Barbato G., De Padova V., Paolillo AR., Arpaia L., Russo E., Ficca G., (2007).** Increased spontaneous eye blink rate following prolonged wakefulness. *Physiol. Behav.* 90:151–154.
- Bast T., da Silva B. M., Morris R. G. M., (2005).** Distinct contributions of hippocampal NMDA and AMPA receptors to encoding and retrieval of one-trial place memory. *J Neurosci*; 25:5845–56.
- Barnard E. A., Skolnick P., Olsen R. W., Mohler H., Sieghart W., Biggio G., Braestrup C., Bateson A. N., Langer S. Z., (1998).** International union of pharmacology, XV. Subtypes of g-aminobutyric acidA receptors: classification on the basis of subunit structure and receptor function, *Pharmacol. Rev.* 50, 291– 313.
- Bayer L, Eggermann E, Serafin M, Saint-Mieux B, Machard D, Jones B, Muhlethaler M., (2001).** Orexins (hypocretins) directly excite tuberomammillary neurons. *Eur J Neurosci* 14:1571-1575
- Bayer L., Serafin M., Eggermann E., Saint-Mieux B., Machard D., Jones BE., Muhlethaler M., (2004).** Exclusive postsynaptic action of hypocretin-orexin on sublayer 6b cortical neurons. *J Neurosci*; 24:6760–6764.
- Bayer L, Colard C, Nguyen NU, Risold PY, Fellmann D, Griffond B.** Alteration of the expression of the hypocretin (orexin) gene by 2-deoxyglucose in the rat lateral hypothalamic area. *Neuroreport* 11:531-533, (2000).
- Bailey K. R., Pavlova M. N., Rohde A. D., Hohmann J. G., Crawley J. H. (2007).** Galanin receptor subtype 2 (GalR2) null mutant mice display an anxiogenic-like phenotype specific to the elevated plus-maze. *Pharmacol Biochem Behav* 86,8–20.
- Balcita-Pedicino JJ, Sesack SR.** Orexin axons in the rat ventral tegmental area synapse infrequently onto dopamine and gamma-aminobutyric acid neurons. *J Comp Neurol* 503: 668-84, (2007).
- Baldo B. A., Alsene K. M., Negron A., Kelley A. E. (2005).** Hyperphagia induced by GABA receptor-mediated inhibition of the nucleus accumbens shell: dependence on intact neural output from the central amygdaloid region. *Behav Neurosci* 119:1195-1206.
- Baron M. S., Wichmann T., Ma D., DeLong M. R. (2002).** Effects of transient focal inactivation of the basal ganglia in parkinsonian primates. *J Neurosci* 22:592-599.
- Baldo BA, Gual-Bonilla L, Sijapati K, Daniel RA, Londry CF, Kelley AE.** Activation of a subpopulation of orexin /hypocretin-containing hypothalamic neurons by GABAA receptor-mediated inhibition of the nucleus accumbens shell, but not by exposure to a novel environment. *Eur J Neurosci* 19:376-386, (2004).

**Ballenger JC.** Treatment of anxiety disorders to remission. *J Clin Psychiatry* 62:5-9, (2001). **Balon N, Kriem B, Weiss M, Rostain JC.** GABAergic modulation in the substantia nigra of the striatal dopamine release and of the locomotor activity in rats exposed to helium pressure. *Brain Res* 948:82-92, (2002).

**Barr A. M., Kinney J. W., Hill M. N., Lu X., Biros S., Rebek Jr J., Bartfai T. (2006).** A novel, systemically active, selective galanin receptor type-3 ligand exhibits antidepressant-like activity in preclinical tests. *Neurosci Lett* 405,111–115.

**Barrera G., Echevarria D. J., Poulin J-F., Laforest S., Drolet G., Morilak D. A. (2005).** One for all or one for one: Does co-transmission unify the concept of a brain galanin “system” or clarify any consistent role in anxiety? *Neuropeptides* 39:289–292.

**Bauer E. P., Schafe G. E., Le Doux J. E. (2002).** NMDA receptors and L-type voltage-gated calcium channels contribute to long-term potentiation and different components of fear memory formation in the lateral amygdala. *J. Neurosci* 22:5239-5242.

**Bear M. F., Connors B. W., Paradiso M. A., (2007).** Neuroscienze. Edizione italiana a cura di Clara Casca., Massimiliano Oliveti., Laura Petrosini. Terza edizione.

**Beck M, Brickley K, Wilkinson HL, Sharma S, Smith M, Chazot PL, Pollard S, Stephenson FA.** Identification, molecular cloning, and characterization of a novel GABAA receptor-associated protein, GRIF-1. *J Biol Chem* 277:30079-30090, (2002).

**Bedford FK, Kittler JT, Muller E, Thomas P, Uren JM, Merlo D, Wisden W, Triller A, Smart TG, Moss SJ.** GABAA receptor cell surface number and subunit stability are regulated by the ubiquitin-like protein Plic-1. *Nat Neurosci* 4:908-916, (2001).

**Behan and Haberly L. B., (1999).** Intrinsic and efferent connections of the endopiriform nucleus in rat. *J Comp Neurol* 408: 532–548.

**Ben-Ari Y, Gaiarsa JL, Tyzio R, Khazipov R.** GABA: A Pioneer Transmitter That Excites Immature Neurons and Generates Primitive Oscillations. *Physiol Rev* 87:1215-1284, (2007).

**Benington JH, Frank MG.** Cellular and molecular connections between sleep and synaptic plasticity. *Prog Neurobiol* 69:77-101, (2003).

**Bennett A O M. R. (2008).** Stress and anxiety in schizophrenia and depression: glucocorticoids, corticotropin-releasing hormone and synapse regression. *Aust N Z J Psychiatry* 42(12):995-1002.

**Bernier PJ, Bédard A, Vinet J, Lévesque M, Parent A.** Newly generated neurons in the amygdala and adjoining cortex of adult primates. *Proc Natl Acad Sci USA* 99:11464-11469, (2002).

**Berridge C. W., Waterhouse B. D., (2003).** The locus coeruleus–noradrenergic system: modulation of behavioral state and state-dependent cognitive processes. *Brain Res. Brain Res. Rev* 42:33–84.

**Berridge K. C., Espana R. A., Vittoz N. M. (2010).** Hypocretin/orexin in arousal and stress. *Brain Res* 1314:91-102.

- Berridge K. C., Robinson T. E. (1998).** What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? *Brain Res. Rev* 28,309-369.
- Berthoud HR, Patterson LM, Sutton GM, Morrison C, Zheng H.** Orexin inputs to caudal raphe neurons involved in thermal, cardiovascular, and gastrointestinal regulation. *Histochem Cell Biol* 123:147-156, (2005).
- Bettler B., Tiao J. Y. (2006).** Molecular Diversity, trafficking and subcellular localization of GABA receptors. *Pharmacol. Ther* 110 (3),533-43.
- Blanco M, Lopez M, Garcia-Caballero T, Gallego R, Vazquez-Boquete A, Morel G, Senaris R, Casanueva F, Dieguez C, Beiras A.** Cellular localization of orexin receptors in human pituitary. *J Clin Endocrinol Metab* 86:1616-1619, (2001).
- Blanco M., Garcia-Caballero T., Fraga M., Gallego R., Cuevas J., Forteza J., Beiras A., Dieguez C. (2002).** Cellular localization of orexin receptors in human adrenal gland, adrenocortical adenomas and pheochromocytomas. *Regul Pept* 104:161-165.
- Blier P., Gobbi G., Haddjeri N., Santarelli L., Mathew G., Hen R. (2004).** Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: relevance to the antidepressant/anxiolytic response. *J. Psychiatry Neurosci* 29,201–208.
- Blouin A. M., Thannikal T. C., Worley P. F., Baraban J. M., Reti I. M., Siegel J. M., (2005).** “Narp immunostaining of human hypocretin (orexin) neurons: loss in narcolepsy”, in *Neurology*, Aug 31.
- Bollan K, Robertson LA, Tang H, Connolly CN.** *Biochem Soc Trans* 31:875-879, (2003).
- Bonci A., Borgland S.( 2009).** Role of orexin/hypocretin and CRF in the formation of drug-dependent synaptic plasticity in the mesolimbic system. *Neuropharmacology* 56(Suppl. 1),107–111.
- Borgland S. L., Malenka R., Bonci A. (2004).** Acute and chronic cocaine-induced potentiation of synaptic strength in the VTA: electrophysiological and behavioral correlates in individual rats. *J Neurosci* 24,7482–7490.
- Borgland S. L., Storm E., Bonci A. (2008).** Orexin B/hypocretin 2 increases glutamatergic transmission to ventral tegmental area neurons. *Eur J Neurosci* 28(8):1545-56.
- Bormann J. (2000).** The “ABC” of GABA receptors. *Trends Pharmacol Sci* 21:16-19.
- Boutrel B., Kenny P. J., Specio S. E., Martin-Fardon R., Markou A., Koob G. F., De Lecea L., (2005).** Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behaviour. *Proc Natl Acad Sci USA* 102:19168-19173.
- Bowmeester H., Smits K., Van ree J. M., (2002).** Neonatal development of projections to the basolateral Amygdala from prefrontal and thalamic structures in rat. *J Comp. Neurol* 450:241-255.
- Braga MF, Aroniadou-Anderjaska V, Manion ST, Hough CJ, Li H.** Stress impairs alpha(1A) adrenoceptor-mediated noradrenergic facilitation of GABAergic transmission in the basolateral amygdala. *Neuropsychopharmacology* 29:45-58, (2004b).

- Britton, K.T., Akwa, Y., Spina, M.G., Koob, G.F., (2000).** Neuropeptide Y blocks anxiogenic-like behavioral action of corticotropin-releasing factor in an operant conflict test and elevated plus maze. *Peptides* 21,37–44.
- Brooks-Kayal AR, Shumate MD, Jin H, Lin DD, Rikhter TY, Holloway KL, Coulter DA.** Human neuronal  $\gamma$ -aminobutyric acid-a receptors: coordinated subunit mRNA expression and functional correlates in individual dentate granule cells. *J Neurosci* 19:8312-8318, (1999).
- Brown S. M., Henning S., Wellman C. L., Mild., (2005).** Short-term stress alters dendritic morphology in rat medial prefrontal cortex. *Cereb Cortex*.15:1714–1722.
- Bubser, M., Fadel J. R., Jackson L. L., Meador-Woodruff J. H., Jing D., Deutch A. Y., (2005).** Dopaminergic regulation of orexin neurons. *Eur. J. Neurosci.* 21:2993–3001.
- Burdakov D, Liss B, Ashcroft FM.** Orexin excites GABAergic neurons of the arcuate nucleus by activating the sodium calcium exchanger. *J Neurosci* 23:4951-4957, (2003).
- Burdakov D., Alexopoulos H., (2005).** Metabolic state signalling through central hypocretin/orexin neurons. *J Cell Mol Med* 9: 795–803.
- Burdakov D., Gerasimenko O., Verkhatsky A. (2005).** Physiological changes in glucose differentially modulate the excitability of hypothalamic melanin-concentrating hormone and orexin neurons in situ. *J. Neurosci* 25 (9) 2429–2433.
- Burdakov D., Jensen L. T., Alexopoulos H., Williams R. H., Fearon I. M., O’Kelly I., Gerasimenko O., Fugger L., Verkhatsky A. (2006).** Tandem-pore K<sup>+</sup> channels mediate inhibition of orexin neurons by glucose. *Neuron* 50 (5) 711–722.
- Burlet S, Tyler CJ, Leonard CS.** Direct and indirect excitation of laterodorsal tegmental neurons by Hypocretin/Orexin peptides: implications for wakefulness and narcolepsy. *J Neurosci* 22:2862-2872, (2002).
- Burrone I, Murthy VN.** Synaptic gain control and homeostasis. *Curr Opin Neurobiol.* 13:560-567, (2003).
- Bush G., Luu P., Posner M. I. (2000).** Cognitive and emotional influences in anterior cingulate cortex. *Trends Cogn Sci* 4:215–222.
- Cahill L., van Stegeren A. (2003).** Sex-related impairment of memory for emotional events with beta-adrenergic blockade. *Neurobiol Learn Mem* 79:81–88.
- Cai X. J., Widdowson P. S., Harrold J., Wilson S., Buckingham R. E., Arch J. R. S., Tadayyon M., Clapham J. C., Williams G. (1999).** Hypothalamic orexin expression: modulation by glucose and feeding. *Diabetes* 48,2132– 2137.
- Cai XJ, Evans ML, Lister CA, Leslie RA, Arch JR, Wilson S and Williams G.** Hypoglycemia activates orexin neurons and selectively increases hypothalamic orexin-B levels: responses inhibited by feeding and possibly mediated by the nucleus of the solitary tract. *Diabetes* 50:105-112, (2001).

- Cai X., Flores-Hernandez J., Feng J., Yan Z., (2002).** Activity-dependent bidirectional regulation of GABA(A) receptor channels by the 5-HT(4) receptor-mediated signalling in rat prefrontal cortical pyramidal neurons. *J. Physiol.* 540 743–759.
- Callado L. F., Hopwood S. E., Hancock P. J., Stamford J. A., (2000).** Effects of dizocilpine (MK801) on noradrenaline, serotonin and dopamine release and uptake. *Neuroreport* 11, 173–176.
- Calvo J. M., Simón-Arceo K. and Ramirez-Salado I., (2001).** The role of temporal lobe amigdala in the onset of REM sleep. *Acta Fisiol* 7:83 (abstract).
- Cardinal R. N., Parkinson J. A., Hall J., and Everitt B. J., (2002).** Emotion and motivation: the role of the amygdala, ventral striatum, and prefrontal cortex. *Neurosci Biobehav Rev* 26: 321–352.
- Carey H. V., Andrews M. T., Martin S. L., (2003).** Mammalian hibernation: cellular and molecular responses to depressed metabolism and low temperature. *Physiol Rev* 83:1153-1181.
- Calandreau L, Desmedt A, Decorte L, Jaffard R.** A different recruitment of the lateral and basolateral amygdala promotes contextual or elemental conditioned association in Pavlovian fear conditioning. *Learn Mem* 12:383-388, (2005).
- Callado L. F., Hopwood S. E., Hancock P. J., Stamford J. A., (2000).**
- Calvo JM, Simón-Arceo K and Ramirez-Salado I.** The role of temporal lobe amigdala in the onset of REM sleep. *Acta Fisiol* 7:83 (abstract), (2001).
- Campbell A. (2008).** Attachment, aggression and affiliation: the role of oxytocin in female social behavior. *Biol Psychol* 77,1–10.
- Capovilla G., Vigevano F. (2001).** Benign idiopathic partial epilepsies in infancy. *J Child Neuro* 16:874-81.
- Cardinal R. N., Parkinson J. A., Hall J., and Everitt B. J., (2002).** Emotion and motivation: the role of the amygdala, ventral striatum, and prefrontal cortex. *Neurosci Biobehav Rev* 26: 321–352.
- Carey HV, Andrews MT, Martin SL.** Mammalian hibernation: cellular and molecular responses to depressed metabolism and low temperature. *Physiol Rev* 83:1153-1181, (2003).
- Carey HV, Mangino MJ, Southard JH.** Changes in gut function during hibernation: implications for bowel transplantation and surgery. *Gut* 49:459-461, (2001).
- Carlisle H. J., Hales T. G., Schlinger B. A. (1998).** Characterization of neuronal zebra finch GABA<sub>A</sub> receptors: steroid effects. *J Comp Physiol A* 182:531-538.
- Cauter EV, Spiegel K.** Circadian and sleep control of hormonal secretions. In: Regulation of sleep and circadian rhythms (Zee PC, Turek FW, eds), 397-425, (1999).
- Chamberlain S. R., Blackwell A. D., Fineberg N. A., Robbins T. W., Sahakian B. J. (2005).** The neuropsychology of obsessive compulsive disorder: the importance of failures in cognitive and behavioural inhibition as candidate endophenotypic markers. *Neurosci Biobehav Rev* 29(3):399-419.



**Chandra D., Jia F., Liang J., Peng Z., Suryanarayanan A., Werner D. F., Spigelman I., Houser C. R., Olsen R. W., Harrison N. L., Homancics G. E. (2006).** GABA<sub>A</sub> receptor  $\alpha$ 4 subunits mediate extrasynaptic inhibition in thalamus and dentate gyrus and the action of gaboxadol. *PNAS USA* 103:15230-15235.

**Charton J. P., Herkert M., Becker C. M., Schronder H., (1999).** Cellular and subcellular localization of the 2B-subunit of the NMDA receptor in the adult rat telencephalon. *Brain Res*; 816:609–17.

**Chen Y., Matsushita M., Nairn A. C., Damuni Z., Cai D., Frerichs K. U., Hallenbeck J. M., (2001).** Mechanisms for increased levels of phosphorylation of elongation factor-2 during hibernation in ground squirrels. *Biochemistry* 40:11565-11570.

**Chenu F., Guiard B. P., Bourin M., Gardier A. M. (2006).** Antidepressant-like activity of selective serotonin reuptake inhibitors combined with a NK1 receptor antagonist in the mouse forced swimming test. *Behav Brain Res* 72,256–263.

**Choleris E., Thomas A. W., Kavaliers M., Prato F. S. (2001).** A detailed ethological analysis of the mouse open field test: effects of diazepam, chlordiazepoxide and an extremely low frequency pulsed magnetic field. *Neurosci Biobehav Rev* 25(3):235-60.

**Chou T. C., Scammell T. E., Gooley J. J., Gaus S. E., Saper C. B., Lu J., (2003).** Critical role of dorsomedial hypothalamic nucleus in a wide range of behavioural circadian rhythms. *J. Neurosci.* 23: 10691-10702.

**Chou TC, Lee CE, Lu J, Elmquist JK, Hara J, Willie JT, Beuckmann CT, Chemelli RM, Sakurai T, Yanagisawa M, Saper CB, Scammell TE.** Orexin (hypocretin) neurons contain dynorphin. *J Neurosci* 21: RC168, (2001).

**Ciriello J, Rosas-Arellano MP, Solano-Flores LP, de Oliveira CVR, (2003).** Identification of neurons containing orexin-B (hypocretin-2) immunoreactivity in limbic structures. *Brain Res* 967:123-131.

**Clayton D. A., Mesches M. H., Alvarez E., Bickford P. C., Browing M. D., (2000).** A hippocampal NR2B deficit can mimic age-related changes in long-term potentiation and spatial learning in the fisher 344 rat. *J Neurosci*; 22:3628– 37.

**Clementi Francesco e Fumagalli Guido, (2004).** *Farmacologia Generale e Molecolare*. terza edizione.

**Cluderay JE, Harrison DC, Hervieu GJ.** Protein distribution of the orexin-2 receptor in the rat central nervous system. *Regul Pept* 104: 131-144, (2002).

**Cook S. C., Wellman C. L., (2004).** Chronic stress alters dendritic morphology in rat medial prefrontal cortex. *J Neurobiol.* 60:236–248.

**Cope D. W., Hughes S. W., Crunelli V. (2005).** GABA<sub>A</sub> receptor-mediated tonic inhibition in thalamic neurons. *J Neurosci* 25:11553-11563.

**Coutinho U., Knopfel T., (2002).** Metabotropic glutamate receptors: electrical and chemical signalling properties. *Neuroscientist* 8:551-561.

**Covault J., Gelernter J., Hesselbrock V., Nellisery M., Kranzler H. R. (2004).** Allelic and haplotypic association of GABRA2 with alcohol dependence. *Am J Med Genet B Neuropsychiatr Genet* 129B:104–109.

**Cream C., Nattie E., Li A., , (1999).** TRH microdialysis into the RTN of the conscious rat increases breathing, metabolism, and temperature. *J Appl Physiol* 87:673-682.

**Crestani F., Keist R., Fritschy J. M., Benke D., Vogt K., Prut L., Blüthmann H., Mohler H., Rudolph U. (2002).** Trace fear conditioning involves hippocampal  $\alpha_5$  GABA<sub>A</sub> receptors. *PNAS USA* 99:8980–8985.

**Cull-Candy S., Brickley S. and Farrant M., (2001).** NMDA receptor subunits: diversity, development and disease. *Curr Opin Neurobiol* 11: 327–335.

**Cushing BS, Mogekwu N, Le WW, Hoffman GE, Carter CS.** Cohabitation induced Fos immunoreactivity in the monogamous prairie vole. *Brain Res* 965:203-211, (2003).

**Cyranowski J. M., Hofkens T.L., Frank E., Seltman H., Cai H. M., Amico J. A. (2008).** Evidence of dysregulated peripheral oxytocin release among depressed women. *Psychosom Med* 70,967–975.

**Da Silva A. A., Marino-Neto J., Paschoalini M. A., (2003).** Feeling induced by microinjections of NMDA and AMPA-kainate receptor antagonists into ventral striatal and ventral pallidal areas of the pigeon. *Brain. Res.* 966: 76-83.

**Darker J. G., Porter R. A., Eggleston D. S., Smart D., Brough S. J., Sabido-David C., Jerman J. C. (2001).** Structure–activity analysis of truncated orexin-A analogues at the orexin-1 receptor. *Bioorg MedChem Lett* 11,737–740.

**Date Y, Mondal MS, Matsukura S, Ueta Y, Yamashita H, Kaiya H, Kangawa K, Nakazato M.** Distribution of orexin/hypocretin in the rat median eminence and pituitary. *Brain Res Mol Brain Res* 76:1-6, (2000b).

**Date Y. Ueta Y., Yamashita H., Yamaguchi H., Matsukura S., Kangawa K., Sakurai T., Yanagisawa M., Nakazato M. (1999).** Orexins, orexigenic hypothalamic peptides, interact with autonomic, neuroendocrine and neuroregulatory systems. *Proc. Natl. Acad. Sci. USA* 96 (2) 748–753.

**Datta S., Mavanji V., Ulloor J., Patterson E. H., (2004).** Activation of phasic pontine-wave generator prevents rapid eye movement sleep deprivation induced learning impairment in the rat: a mechanism for sleep-dependent plasticity. *J Neurosci* 24:1416-1427.

**Davidson J., Bjorgvinsson T. (2003).** Current and potential pharmacological treatments for obsessive-compulsive disorder. *Expert Opin Investig Drugs* 12 (6),993–1001.

**Davidson R. J. (2002).** Anxiety and affective style: Role of prefrontal cortex and amygdala. *Biol Psychiatry* 51:68–80.

**Davis M. (2006).** Neural systems involved in fear and anxiety measured with fear-potentiated startle. *Am Psychol* 61:741–756.

- Davis M. and Whalen P. J., (2001).** The amygdala: vigilance and emotion. *Mol Psychiatry* 6: 13–34.
- Davis M.** Role of NMDA receptors and MAP kinase in the amygdala in extinction of fear: clinical implications for exposure therapy. *Eur J Neurosci* 16:395-398, (2002).
- Day H. E., Curran E. J., Watson S. J. J. R., and Akil H., (1999).** Distinct neurochemical populations in the rat central nucleus of the amygdala and bed nucleus of the stria terminalis: evidence for their selective activation by interleukin-1beta. *J Comp Neurol* 413: 113–128.
- De La Garza, R., Mahoney, J. J., (2004).** A distinct neurochemical profile in WKY rats at baseline and in response to acute stress: implications for animal models of anxiety and depression. *Brain Research* 1021 (2), 209–218.
- Delaney, A.J. Sah P., (1999)** GABA receptors inhibited by benzodiazepines mediate fast inhibitory transmission in the central amygdala. *Neurosci.* 199698–9704.
- De Lecea L., Sutcliffe J. G. (2005).** The hypocretins and sleep. *FEBS J* 272:5675-5688.
- De Lecea L., Kilduff T. S., Peyron C., Gao X. B., Foye P. E., Danielson P. E., Fukuhara C., Battenberg E. L. F., Gautvik V. T., Bartlett II F., Frankel W. N., Van den Pol A. N., Bloom F. E., Gautvik K. M, Sutcliffe J. G., (1998).** The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. *Proc. Natl. Acad. Sci.* 95:322-7
- Denys D., Van Der Wee N., Janssen J., De Geus F., Westenberg H. G. (2004).** Low level of dopaminergic D(2) receptor binding in obsessive–compulsive disorder. *Biol Psychiatry* 55 (10),1041–1045.
- De Olmos K., Beltramino C. A., De Olmos De Lorenzo S. (1994).** Use of a fan amino-cupric silver technique for the detection of early and semiacute neuronal degeneration caused by neurotoxicants, hypoxia, and physical trauma. *Neurotox Teratol* 16:545-561.
- Desai N. S., Cudmore R. H., Nelson S. B., Turrigiano G. G., (2002).** Critical periods for experience dependent synaptic scaling in visual cortex. *Nature Neurosci* 5:783-789.
- Di Micco J. A., Samuels B. C., Zaretskaia M. V., Zaretsky D. V. (2002).** The dorsomedial hypothalamus and the response to stress: part renaissance, part devolution. *Pharmacol Biochem Behav* 71:469-480.
- Dias R., Sheppard W. F., Fradley R. L., Garrett E. M., Stanley J. L., Tye S. J., Goodacre S., Lincoln R. J., Cook S. M., Conley R., Hallett D., Humphries A. C., Thompson S. A., Wafford K. A., Street L. J., Castro J. L., Whiting P. J., Rosahl T. W., Atack J. R., McKernan R. M., Dawson G. R., Reynolds D. S. (2005)** Evidence for a significant role of alpha 3-containing GABAA receptors in mediating the anxiolytic effects of benzodiazepines. *J Neurosci* 25:10682–10688. [PubMed: 16291941].
- Dong H. W., Petrovic G. D. and Swanson L. W., (2001).** Topography of projections from amygdala to bed nuclei of the stria terminalis. *Brain Res* 38: 192–246.

- Drew K. L., Rice M. E., Kuhn T. B., Smith M. A. (2001).** Neuroprotective adaptations in hibernation: therapeutic implications for ischemia-reperfusion, traumatic brain injury and neurodegenerative diseases. *Free Radical Biol Med* 31:563-573.
- Dube M. G., Kalra S. P., Kalra P. S. (1999).** Food intake elicited by central administration of orexin/hypocretins: identification of hypothalamic sites of action. *Brain Res* 842:472-473.
- Dube MG, Horvath TL, Kalra PS, Kalra SP.** Evidence of NPY Y5 receptor involvement food intake elicited by orexin A in sated rats. *Peptides* 21:1557-1560, (2000).
- Dunlop B. W., Nemeroff C. B., (2007).** The role of dopamine in the pathophysiology of depression. *Archives of General Psychiatry* 64 (3), 327–337.
- Duva M. A., Tomkins E. M., Moranda L. M., Kaplan R., Sukhaseum A., Stanley B. G., (2005).** Origins of lateral hypothalamic afferents associated with *N*-methyl-D-aspartic acid-elicited eating studied using reverse microdialysis of NMDA and Fluorogold. *Neurosci Res* 52: 95–106.
- Ebner K., Rupniak N. M., Saria A., Singewald N. (2004).** Substance P in the medial amygdala: emotional stress-sensitive release and modulation of anxiety-related behavior in rats. *Proc Natl Acad Sci USA* 101,4280–4285.
- Ebner K., Sartori S. B., Singewald N. (2009).** Tachykinin receptors as therapeutic targets in stress-related disorders. *Curr Pharm Des* 15,1647–1674.
- Ebner K., Singewald N. (2006).** The role of substance P in stress and anxiety responses. *Amino Acids* 31,251–272.
- Edenberg H. J., Dick D. M., Xuei X., Tian H., Almasy L., Bauer L. O., Crowe R. R., Goate A., Hesselbrock V., Jones K., Kwon J., Li T. K., Nurnberger J. I. Jr, O'Connor S. J., Reich T., Rice J., Schuckit M. A., Porjesz B., Foroud T., Begleiter H. (2004).** Variations in GABRA2, encoding the alpha 2 subunit of the GABA(A) receptor, are associated with alcohol dependence and with brain oscillations. *Am J Hum Genet* 74:705–714.
- Eggermann E., Serafin M., Bayer L., Machard D., Saint-Mleux B., Jones B. E., Muhlethaler M., (2001).** Orexins/hypocretins excite basal forebrain cholinergic neurones. *Neuroscience* 108:177-181.
- Eggers A. E. (2007).** Redrawing Papez' circuit: a theory about how acute stress becomes chronic and causes disease. *Med Hypothesis* 69:852–7.
- Ehstrom M., Gustafsson T., Finn A., Kirchgessner A., Gryback P., Jacobsson H., Hellstrom P. M., Naslund E., (2005).** Inhibitory effect of exogenous orexin A on gastric emptying, plasma leptin, and distribution of orexin and orexin receptors in the gut and pancreas in man. *J. Clin. Endocrinol. Metab.* 90: 2370-2377.
- Eiland M. M., Ramanathan L., Gulyani S., Gilliland M., Bergmann B. M., Rechtschaffen A., Siegel J. M. (2002).** Increases in amino-cupric-silver staining of the supraoptic nucleus after sleep deprivation. *Brain Res* 945(1):1-8.

**Elliott-Hunt C. R., Pope R. J., Vanderplank P., Wynick D. (2007).** Activation of the galanin receptor 2 (GalR2) protects the hippocampus from neuronal damage. *J Neurochem* 100,780-789.

**Elmqvist JK, Elias CF, Saper CB.** From lesions to leptin: hypothalamic control of food intake and body weight. *Neuron* 22:221-232, (1999).

**Elshourbagy N. A., Bergsma D. J., Yanagisawa M., (1998).** Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. *Cell* 92: 573–585.

**Endo K., Hori T., Abe S. (2007).** Alterations in GABA (A) receptor expression in neonatal ventral hippocampal lesioned rats: comparison of prepubertal and postpubertal periods. *Synapse* 61:357-366.

**Enoch M. A., Schwartz L., Albaugh B., Virkkunen M., Goldman D. (2006).** Dimensional anxiety mediates linkage of GABRA2 haplotypes with alcoholism. *Am J Med Genet B Neuropsychiatr Genet* 141:599–607

**Eriksson KS, Wren J, Loyd D, Warden K., (1999).**A comparison between in vitro studies of protein lesions generated by brain electrodes and finite element model stimulation, *Med Biol Eng Comput* 377:737-741.

**Eriksson K. S., Sergeva O. A., Selbach O., Haas H. L. (2004).** Orexin (hypocretin)/dynorphin neurons control GABAergic inputs to tuberomammillary neurons. *Eur J Neurosci* 19:1278-1284.

**Espana R. A., Valentino R. J., Berridge C. W. (2003).** Fos immunoreactivity in hypocretin-synthesizing and hypocretin-1 receptor-expressing neurons: effects of diurnal and nocturnal spontaneous waking, stress and hypocretin- 1 administration. *Neuroscience* 121,201–217.

**Espana R. A., Plahn S., Berridge C. W., (2002).** Circadian-dependent and circadian-independent behavioral actions of hypocretin/ orexin. *Brain Res.* 943, 224–236.

**Espana RA, Baldo BA, Kelley AE, Berridge CW.** Wake-promoting and sleep-suppressing actions of hypocretin (orexin): basal forebrain sites of action. *Neuroscience* 106: 699-715, (2001). *Neurosci* 21,1656–1662.

**Estabrooke I. V., McCarthy M. T., Ko E., Chou T. C., Chemelli R. M., Yanagisawa, M., Saper C. B., Scammell T. E. (2001).** Fos expression in orexin neurons varies with behavioral state. *J.*

**Everitt B. J., Cardinal R. N., Hall J., Parkinson J. A., Robbins J. A. and Robbins T. W., (2000).** Differential involvement of amygdala subsystems in appetitive conditioning and drug addiction. In: *The Amygdala: A Functional Analysis (2nd ed.)*, edited by Aggleton JP. New York: Oxford Univ. Press, p. 353–390.

**Eyigor O., Centers A., Jennes L., (2001).** Distribution of ionotropic glutamate receptor subunit mRNAs in the rat hypothalamus. *J. Comp. Neurol* 434: 101-124.

**Faber E. S. L., Callister R. J., Sah P. (2001).** Morphological and electrophysiological properties of principal neurons in the rat lateral amygdala in vitro. *J Neurophysiol* 85:714-723

- Fabris C., Cozzi B., Hay-Schmidt A., Naver B., Møller M., (2004).** Demonstration of an orexinergic central innervation of the pineal gland of the pig. *J. Comp. Neurol.* 471: 113-127.
- Fadel J., Bubser M., Deutch AY., (2002).** Differential activation of orexin neurons by antipsychotic drugs associated with weight gain. *J Neurosci*; 22:6742–6746.
- Fanselow M. S., (2000).** Contextual fear, gestalt memories, and the hippocampus. *Behav Brain Res*;110:73–8.
- Farrant M., Kaila K. (2007).** The cellular, molecular and ionic basis of GABA(A) receptor signalling. *Prog Brain Res* 160:59-87.
- Faulkner B. and Brown TH., (1999).** Morphology and physiology of neurons in the rat perirhinal-lateral amygdala area. *J Comp Neurol* 411: 613–642.
- Feng J., Cai X., Zhao J., Yan Z., (2001).** Serotonin receptors modulate GABA(A) receptor channels through activation of anchored protein kinase C in prefrontal cortical neurons, *J. Neurosci.* 21 (17) 6502–6511.
- Finnegan T. F., Chen S. R., Pan H. L. (2005).** Effect of the  $\mu$ opioid on excitatory and inhibitory synaptic inputs to periaqueductal gray-projecting neurons in the amygdala. *J Pharmacol Exp Ther* 312:441-448.
- Follesa P., Biggio F., Talani G., Murru L., Serra M., Sanna E., Biggio G. (2006).** Neurosteroids, GABA<sub>A</sub> receptors, and ethanol dependence. *Psychopharmacology* 186:267-280.
- Franczek R., Boumann C. R., Lammers G. J., Bassetti C. L., Overeems., (2008).** Hypocretin-orexin disturbance in neurological disorders.
- Frey S, Bergado-Rosado J, Seidenbecher T, Pape HC, Frey JU.** Reinforcement of early long-term potentiation (early-LTP) in dentate gyrus by stimulation of the basolateral amygdala: heterosynaptic induction mechanisms of late-LTP. *J Neurosci* 21:3697-3703, (2001).
- Frey S., Frey J. U. (2008).** ‘Synaptic tagging’ and ‘cross-tagging’ and related associative reinforcement processes of functional plasticity as the cellular basis for memory formation. *Prog Brain Res* 169,117–143.
- Fritschy J. M., Crestani F., Rudolph U., Mohler H. (2004).** GABA<sub>A</sub> receptor subtype with special reference to memory function and neurological disorders. In: Hensch TK, Fagiolini M (eds) *Excitatory inhibitory balance: synapses, circuits and systems plasticity*. Kluwer Academic/Plenum, New York pp 215-228.
- Frucht MM, Quigg M, Schwaner C, Fountain NB.** Distribution of seizure precipitants among epilepsy syndromes. *Epilepsia* 41:1534-1539, (2000).
- Furmark T., Appel L., Michelgård A., Wahlstedt K., Ahs F., Zancan S., Jacobsson E., Flyckt K., Grohp M., Bergström M., Pich E. M., Nilsson L. G., Bani M., Långström B., Fredrikson M. (2005).** Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. *Biol Psychiatry* 58,132–142.

- Fujiki N., Yoshida Y., Ripley B., Honda K., Mignot E., Nishino S., (2001).** Changes in CSF hypocretin- 1 (orexin A) levels in rats across 24 hours and in response to food deprivation. *Neuroreport* 12:993-997.
- Gais S., Born J., (2004).** Declarative memory consolidation: Mechanisms acting during human sleep. *Learn Mem* 11:679-685.
- Galanopoulou AS.** GABAA receptors in normal development and seizures: friends of foes? *Curr Neuropharmacol* 6:1-20, (2008b).
- Gao X. B., van den Pol A. N., (2001).** Melanin concentrating hormone depresses synaptic activity of glutamate and GABA neurons from rat lateral hypothalamus. *J Physiol* 533: 237–252.
- Geiser F., (2004).** Metabolic rate and body temperature reduction during hibernation and daily torpor. *Annu Rev Physiol* 66: 239-274.
- Gerashchenko D., Salin-Pascual R., Shiromani P. J. (2001).** Effects of hypocretin-saporin injections into the medial septum on sleep and hippocampal theta. *Brain Research* 913:106-115.
- Gimpl G., Fahrenholz F. (2001).** The oxytocin receptor system: structure, function, and regulation. *Physiol Rev* 81,629–683.
- Glykys J., Mann E. O., Mody I. (2008).** Which GABA<sub>A</sub> receptor subunits are necessary for tonic inhibition in the hippocampus? *J Neurosci* 28:1421-1426.
- Goddard A. W., Mason G. F., Almai A., Rothman D. L., Behar K. L., Petroff O. A., Charney D. S., Krystal J. H. (2001).** Reductions in occipital cortex GABA levels in panic disorder detect with <sup>1</sup>H-magnetic resonance spectroscopy. *Arch Gen Psychiatry* 58:556-56.
- Gomperts S. N., Carroll R., Marenka R. C., Nicoll R. A., (2000).** Distinct roles for ionotropic and metabotropic glutamate receptors in the maturation of excitatory synapses. *J Neurosci* 20: 2229-2237.
- Goodkin H. P., Joshi S., Mtchedlishvili Z., Brar J., Kapur J. (2008).** Subunit-specific trafficking of GABA<sub>A</sub> receptors during status epilepticus. *J Neurosci* 28:2527-2538.
- Goosens K. A. and Maren S., (2001).** Contextual and auditory fear conditioning are mediated by the lateral, basal, and central amygdaloid nuclei in rats. *Learn Mem* 8: 148–155.
- Gorman J. M., Kent J. M., Sullivan G. M., Coplan J. D. (2000).** Neuroanatomical hypothesis of panic disorder. *Am J Psychiatry* 157:493-505.
- Gorwood P. (2004).** Generalized anxiety disorder and major depressive disorder comorbidity: an example of genetic pleiotropy? *Eur Psychiatry* 19(1):27-33.
- Graybiel A. M., Rauch S. L. (2000).** Toward a neurobiology of obsessivecompulsive disorder. *Neuron* 28 (2),343–347.
- Greco M. A., Shiromani P. J. (2001).** Hypocretin receptor protein and mRNA expression in the dorsolateral pons of rat. *Brain Res Mol Brain Res* 88:176-182.

- Guastella, A.J., Howard, A.L., Dadds, M.R., Mitchell, P., Carson, D.S., (2009).** A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder. *Psychoneuroendocrinology* 34,917–923.
- Guiard B. P., Przybylski C., Guilloux J. P., Seif I., Froger N., De Felipe C., Hunt S. P., Lanfumey L., Gardier A. M. (2004).** Blockade of substance P (neurokinin 1) receptors enhances extracellular serotonin when combined with a selective serotonin reuptake inhibitor: an in vivo microdialysis study in mice. *J Neurochem* 89,54–63.
- Hagan J., Leslie R. A., Patel S., Evans M. L., Wattam T. A., Holmes S., Benham C. D., Taylor S. G., Routledge C., Hemmati P., Munton R. P., Ashmeade T. E., Shah A. S., Hatcher J. P., Hatcher P. D., Jones D. N. C., Smith M. I., Piper D. C., Hunter A. J., Porter R. A., Upton N. (1999).** Orexin A activates locus coeruleus cell firing and increases arousal in the rat. *Proc Natl Acad Sci USA* 96 10911–10916.
- Hahn B., Shoaib M., Stolerman I. P., (2003).** Involvement of the prefrontal cortex but not the dorsal hippocampus in the attention-enhancing effects of nicotine in rats. *Psychopharmacology (Berl)*. 168:271–279.
- Haj-Dahmane S., Shen R. S. (2005).** The wake-promoting peptide Orexin-B inhibits glutamatergic transmission to dorsal raphe nucleus serotonin neurons through retrograde endocannabinoid signaling. *J Neurosci* 25(4):896-905.
- Haller J., Leveleki C., Halasz J., Baranyi J., Makara G. B. (2001).** The effect of glucocorticoids on the anxiolytic efficacy of buspirone. *Psychopharmacology (Berl)* 157(4):388-394.
- Hamke M., Herpfer I., Lieb K., Wandelt C., Fiebich B. L. (2006).** Substance P induces expression of the corticotropin-releasing factor receptor 1 by activation of the neurokinin-1 receptor. *Brain Res* 1102(1):135-44.
- Hara J., Beuckmann C. T., Nambu T, Willie J. T., Chemelli R. M., Sinton C. M., Sugiyama F., Yagami K., Goto K., Yanagisawa M and Sakurai T., (2001).** Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. *Neuron* 30,345–354.
- Hara J., Beuckmann C. T., Nambu T., Willie J. T., Chemelli R. M., Sinton C. M., Sugiyama F., Harris G. C., Aston-Jones G., (2006).** Arousal and reward: a dichotomy in orexin function. *TRENDS Neurosci* 29:572-577.
- Harris G. C, Aston-Jones G., (2006).** Arousal and reward: a dichotomy in orexin function. *Trends Neurosci* 29: 571–577.
- Harris G. C., Wimmer M., Jones G. A. (2005).** A role for lateral hypothalamic orexin neurons in reward seeking. *Nature* 437:556–559.
- Hayden E. P, Nurnberger Jr J. I. (2006).** Molecular genetics of bipolar disorder. *Genes Brain Behav* 5:85–95.



- Haynes A. C., Jackson b., Chapman H., Tadayyon M., Johns A., Porter R. A., Arch J. R. S. (2000).** A selective orexin-1 receptor antagonist reduces food consumption in male and female rats. *Regul Pept* 96,45-51.
- Heinbockel T. and Pape H. C., (2000).** Input-specific long-term depression in the lateral amygdala evoked by theta frequency stimulation. *J Neurosci* 20: RC68.
- Hendelman W. (2000).** Atlas of Fuctional Neuroanatomy. *Boca Raton, Fla: CRC Press, LLC.*
- Henny P. and Jones B. E., (2006).** Innervation of orexin/hypocretin neurons by GABAergic, glutamatergic or cholinergic basal forebrain terminals evidenced by immunostaining for presynaptic vesicular transporter and postsynaptic scaffolding proteins. *J. Comp. Neurol.* 499:645–661.
- Hervieu G. J., Cluderay J. E., Harrison D. C., Roberts J. C., Leslie R. A., (2001).** Gene expression and protein distribution of the orexin-1 receptor in the rat brain and spinal cord. *Neuroscience; 103:777–797.*
- Hirota K., Kudo M., Kudo T., Matsuki A., Lambert G., (2000).** Inhibitory effects of intravenous anaesthetic agents on K<sup>+</sup> - evoked norepinephrine and dopamine release from rat striatal slices: possible involvement of P/Q-type voltage-sensitive Ca<sup>2+</sup> channels. *Br. J. Anaesth.* 85, 874–880.
- He X. P., Kotloski R., Nef S., Luikart B. W., Parada L. F., McNamara J. O. (2004).** Conditional deletion of TrkB but not BDNF prevents epileptogenesis in the kindling model. *Neuron* 43:31-42.
- He Y., Kudo M., Kudo T., Kushikata T., Li E., Hirota K. (2007).** The effects of Benzodiazepines on Orexinergic Systems in Rat Cerebrocortical Slices. *International Anesthesia Research Society*
- Hirota K., Kushikata T., Kudo M., Kudo T., Lambert D. G., Matsuki A., (2001).** Orexin A and B evoke noradrenaline release rom rat cerebrocortical slices. *Br. J. Pharmacol.* 134, 1461–1466.
- Hobson S. A., Bacon A., Elliot-Hunt C. R., Holmes F. E., Kerr N.C., Pope R., Vanderplank P. Wynick D. (2008).** Galanin acts as a trophic factor to the central and peripheral nervous systems. *Cell Mol Life Sci* 65,1806–1812.
- Hodgson R. A., Higgins G. A., Guthrie D. H., Lu S. X., Pond A. J., Mullins D. E., et al. (2007).** Comparison of the V1b antagonist, SSR149415, and the CRF1 antagonist, CP- 154,526, in rodent models of anxiety and depression. *Pharmacol Biochem Behav* 86:431–40.
- Hoffman K. L., McNaughton B. L., (2002).** Coordinated reactivation of distributed memory traces in primate cortex. *Science* 297:2070-2073.
- Hoge E. A., Pollack M. H., Kaufman R. E., Zak P. J., Simon N. M. (2008).** Oxytocin levels in social anxiety disorder. *CNS Neurosci Ther* 14,165–170.
- Holmes A., Lit Q., Murphy D. L., Gold E., Crawley J. N. (2003a).** Abnormal anxiety-related behavior in serotonin transporter null mutantmice: the influence of genetic background. *Genes Brain Behav* 2 (6),365–380.

**Holmes A., Murphy D. L., Crawley J. N. (2003b).** Abnormal behavioral phenotypes of serotonin transporter knockout mice: parallels with human anxiety and depression. *Biol Psychiatry* 54 (10),953–959.

**Holmqvist T., Åkerman K. E. O., Kukkonen J. P., (2001).** High specificity of human orexin receptors for orexins over neuropeptide Y and other neuropeptides. *Neurosci Lett* 305:177-180.

**Holsboer F. (2003).** Corticotropin-releasing hormone modulators and depression. *Curr Opin Investig Drugs* 4:46–50.

**Holsboer F., (2000).** The corticosteroid receptor hypothesis of depression *Neuropsychopharmacology* 23,477–501.

**Horvath T. L., Diano S. and van den Pol A. N., (1999b).** Synaptic interaction between hypocretin (orexin) and neuropeptide Y cells in the rodent and primate hypothalamus: a novel circuit implicated in metabolic and endocrine regulations. *J Neurosci* 19,1072–1087

**Horvath T. L., Diano S., & Van den Pol A. N. (1999a).** Synaptic interaction between hypocretin (orexin) and neuropeptide Y cells in the rodent and primate hypothalamus: a novel circuit implicated in metabolic and endocrine regulations. *J Neurosci* 19,1072– 1087.

**Horvath T. L., Peyron C., Diano S., et al. (1999).** Hypocretin (orexin) activation and synaptic innervations of the locus coeruleus noradrenergic system. *J. Comp Neurol* 415:145-59.

**Horvath TL, Gao XB.** Input organization and plasticity of hypocretin neurons: possible clues to obesity's association with insomnia. *Cell Metab* 1:279-286, (2005).

**Horvath TL, Peyron C, Diano S, Ivanov A, Aston-Jones G, Kilduff TS, van Den Pol AN.** Hypocretin (orexin) activation and synaptic innervation of the locus coeruleus noradrenergic system. *J Comp Neurol* 415:145-159, (1999a).

**Huang H., Ghosh P., van den Pol A. N., (2006).** Prefrontal cortex projecting glutamatergic thalamic paraventricular nucleus excited by hypocretin: a feedforward circuit that may enhance cognitive arousal. *J Neurophysiol.* 95:1656–1668.

**Huang Z. L., Qu W. M., Li W. D., Mochizuki T., Eguchi N., Watanabe T., Urade Y., Hayaishi O. (2001).** Arousal effect of Orexin A depends on activation of the histaminergic system. *Proc Natl Acad Sci U S A* 98:9965-9970.

**Huang ZL, Sato Y, Mochizuki T, Okada T, Qu WM, Yamatodani A, Urade Y, Hayaishi O.** Prostaglandin E2 activates the histaminergic system via the EP4 receptor to induce wakefulness in rats. *J Neurosci* 23:5975-5983, (2003).

**Huber D., Veinante P., Stoop R. (2005).** Vasopressin and oxytocin excite distinct neuronal populations in the central amygdala. *Science* 308,245–248.

**Huber R., Ghilardi M. F., Massimini M., Tononi G., (2004).** Local sleep and learning. *Nature* 430:78-81.

- Ida T., Nakahara K., Murakami T., HanadaR., Nakazato M., Murakami M. (2000).** Possible involvement of orexin in the stress reaction in rats, *Biochem. Biophys. Res. Commun* 270:318–323.
- Inoue Y., Takayama C. (2004).** Transient expression of GABAA receptor alpha2 and alpha3 subunits in differentiating cerebellar neurons. *Brain Res Dev Brain Res* 148(2):169-77.
- Jaskolski F., Coussen F., Mulle C., (2005).** Subcellular localization and trafficking of kainite receptors. *Trends Pharmacol. Sci.* 26: 20-26.
- Jaszberenyi M., Bujdoso E., Pataki I., Telegdy G. (2000).** Effects of orexins on the hypothalamic – pituitary–adrenal system. *J Neuroendocrinol* 12:1174–1178.
- Jensen ML, Timmermann DB, Johansen TH, Schousboe A, Varming T, Ahring PK.** The beta subunit determines the ion selectivity of the GABAA receptor. *J Biol Chem* 277:41438-41447, (2002).
- John J., Wu M. F., Kodama T., Siegel J. M. (2001).** Hypocretin-1 (orexin-A) produced changes in glutamate and GABA release: an *in vivo* microdialysis study. *Sleep* 24:A20.
- John J., Wu M. F., Kodama T., Siegel J. M., (2003).** Intravenously administered hypocretin-1 alters brain amino acid release: an *in vivo* microdialysis study in rats. *J Physiol* 548: 557–562.
- Johren O., Neidert S. J., Kummer M., Dendorfer A. and Dominiak P., (2001).** Prepro-orexin and orexin receptor mRNAs are differentially expressed in peripheral tissues of male and female rats. *Endocrinology* 142:3324-3331.
- Jolkkonen E. and Pitkanen A., (1998).** Intrinsic connections of the rat amygdaloid complex: projections originating in the central nucleus. *J Comp Neurol* 395: 53–72.
- Jones B. E. (2003).** Arousal system. *Front Biosci* 8:438-451.
- Jones B. E., Muhlethaler M. (2005).** Modulation of cortical activity and sleep/wake state by hypocretin/orexin. In: *de Lecea L, Sutcliffe JG, editors. The hypocretins: integrators of physiological systems. New York: Springer* 289-301.
- Jones BE.** Activity, modulation and role of basal forebrain cholinergic neurons innervating the cerebral cortex. *Prog Brain Res* 145:157-169, (2004).
- Jones D.N., Gartlon J., Parker F., Taylor S. G., Routledge C., Hemmati P., Munton R. P., Ashmeade T. E., Hatcher J. P., Johns A., Porter R. A., Hagan J. J., Hunter A. J., Upton N. (2001).** Effects of centrally administered orexin-B and orexin-A: a role for orexin-1 receptors in orexin-B-induced hyperactivity. *Psychopharmacology* 53(2):210-8.
- Jones S. R., Fernyhough C., (2006).** A New Look at the Neural Diathesis- Stress Model of Schizophrenia: The Primacy of Social- Evaluative and Uncontrollable Situations. *Schizophr Bull.* doi: 10.1093/schbul/sbl058. 40. Brown SM, Henning S, Wellman C.
- Jonnal A. H., Gardner C. O., Prescott C. A., Kendler K. S. (2000).** Obsessive and compulsive symptoms in a general population sample of female twins. *Am J Med Genet* 96 (6),791–796.

**Jovanovic J. N., Thomas P., Kittler J. T., Smart T. G., Moss S. J. (2004).** Brain-derived neurotrophic factor modulates fast synaptic inhibition by regulating GABA(A) receptor phosphorylation, activity, and cell-surface stability. *J Neurosci* 24:522-30.

**Juri Fujimura., Masatoshi Nagano., Hidenori Suzuki., (2005).** Differential expression of GABA-A receptor subunits in the distinct nuclei of the rat Amigdala. *Dip. Pedriaticc-Pharmacologia* 113-8602.

**Kageyama H., Kita T., Toshinai K., Guan JL., Date Y., Takenoya F., Kato S., Matsumoto H., Ohtaki T., Nakazato M., Shioda S., (2006).** Galanin-like peptide promotes feeding behaviour via activation of orexinergic neurones in the rat lateral hypothalamus. *J Neuroendocrinol* 18: 33–41.

**Kang-Park M. K., Wilson W. A., Moore S. D., (2004).** Differential actions of diazepam and zolpidem in basolateral and central amygdala nuclei, *Neuropharmacology* 46-1 – 9. **Karteris E.,**

**Chen J., Randeve H. S., (2004).** Expression of human prepro- orexin and signalling characteristics of orexin receptors in the male reproductive system. *J. Clin. Endocrinol. Metab.* 89: 1957-1962

**Kandel ER. (2001).**The molecular biology of memory storage: a dialogue between genes and synapses. *Science* 294:1030-1038.

**Kang-Park M. H., Wilson W. A., Moore S. D. (2004).** Differential actions of diazepam and zolpidem in basolateral and central amygdala nuclei. *Neuropharmacology* 46:1-9.

**Kaplan A., Hollander E. (2003).** A review of pharmacologic treatments for obsessive-compulsive disorder. *Psychiatr. Serv* 54 (8),1111–1118.

**Kash TL, Trudell JR, Harrison NL. (2004).** Structural elements involved in activation of the  $\gamma$ -aminobutyric acid type A (GABA<sub>A</sub>) receptor. *Biochem Soc Trans* 32:540-546.

**Kask A., Harro J., von Hörsten S., Redrobe J. P., Dumont Y., Quirion R. (2002).** The neurocircuitry and receptor subtypes mediating anxiolytic-like effects of neuropeptide Y. *Neurosci. Biobehav. Rev* 26, 258–259.

**Kaslin J., Nystedt J. M. Ostergard M., Peitsaro N., Panula P. (2004).** The orexin/hypocretin system in zebrafish in connected to the aminergic and cholinergic system. *J Neurosci* 24,2678-2689.

**Kasparov S., Davies K. A., Patel U. A., Boscan P., Garret M., Paton J. F. R., (2001).**GABAA receptor (subunit– subunit may confer benzodiazepine insensitivity to the caudal aspect of the nucleus tractus solitarii of the rat, *J. Physiol.* 536 785– 796.

**Kalin N. H., Shelton S. E., Davidson R. J. (2004).**The role of the central nucleus of the amygdala in mediating fear and anxiety in the Primate. *J Neurosci* 24:5506-5515.

**Kauer J. A. (2004).** Learning mechanisms in addiction: synaptic plasticity in the ventral tegmental area as a result of exposure to drugs of abuse. *Annu Rev Physiol* 66:447-75.

**Kaufmann W. A., Humpel C., Alheid G. F., Marksteiner J., (2003).** Compartmentation of alpha 1 and alpha 2 GABAA receptor subunits within rat extended amygdala: implications for benzodiazepine action, *Brain Res.* 964-91– 99.

- Kayaba Y., Nakamura A., Kasuya Y., Ohuch, T., Yanagisawa M., Komuro I., Fukuda Y., Kuwaki T. (2003).** Attenuated defense response and low basal blood pressure in orexin knockout mice. *Am J Physiol Regul Integr Comp Physiol* 285(3):R581-93.
- Keck M. E., Welt T., Wigger A., Renner U., Engelmann M., Holsboer F., Landgraf R. (2001).** The anxiolytic effect of the CRH(1) receptor antagonist R121919 depends on innate emotionality in rats. *Eur J Neurosci* 13:373–80.
- Keller M., Baum M. J., Brock O., Brennan P. A., Bakker J. (2009).** The main and the accessory olfactory systems interact in the control of mate recognition and sexual behavior. *Behav Brain Res* 200(2):268-76.
- Keller M., Montgomery S., Ball W., Morrison M., Snavelly D., Liu G., Hargreaves R., Hietala J., Lines C., Beebe K., Reines S. (2006).** Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. *Biol Psychiatry* 59(3):216-23.
- Kelley A. E., Baldo B. A., Pratt W. E., Will M. J. (2005).** Corticostriatal hypothalamic circuitry and food motivation: Integration of energy, action and reward. *Physiol Behav* 86:773–95.
- Kellner M., Schick M., Yassouridis A., Struttmann T., Wiedemann K., Alm B. (2004).** Metyrapone tests in patients with panic disorder. *Biol Psychiatry* 56:898–900.
- Kempainen S. and Pitkanen A., (2000).** Distribution of parvalbumin, calretinin, and calbindin-D(28k) immunoreactivity in the rat amygdaloid complex and colocalization with gamma-aminobutyric acid. *J Comp Neurol* 426: 441–467.
- Khatami R., Maret S., Werth E., Retev J., Schmid D., Maly F., Tafti M., Bassetti C. L., (2004).** “Monozygotic twins concordant for narcolepsy-cataplexy without any detectable abnormality in the hypocretin (orexin) pathway”, in *Lancet Apr 10, 363 (9416), pag. 1199-2000.*
- Kilduff T. S., de Lecea L., (2001).** Mapping of the mRNAs for the hypocretin/orexin and melanin concentrating hormone receptors: networks of overlapping peptide systems. *J Comp Neurol* 435: 1–5.
- Kirchgessner A. L., (2002).** Orexins in the brain-gut axis. *Endoc. Rev.*23: 1-15. **Kiyama Y., Manabe T., Sakimura K., Kawakami F., Mori H., Mishina M., (1998).** Increased thresholds for long-term potentiation and contextual learning in mice lacking the NMDA-type glutamate receptor  $\epsilon 1$  subunit. *J Neurosci*; 18:6704.
- Kodama T., Kimura M., (2002).** Arousal effects of orexin-A correlate with Glu release from the locus coeruleus in rats. *Peptides* 23: 1673–1681.
- Kohsaka A., Watanobe H., Kakizaki Y., Suda T., Shioth H. B., (2001).** A significant participation of orexin A, a potent orexigenic peptide, in the preovulatory luteinizing hormone and prolactin surges in the rat. *Brain. Res.* 898: 166-170.
- Kokare D. M., Patole A. M., Carta A., Chopde C. T., Subhedar N. K., (2006).** GABAA receptors mediate orexin-A induced stimulation of food intake. *Neuropharmacol* 50:16-24.

- Koo J. W., Han J. S., Kim J. J., (2004).** Selective neurotoxic lesions of basolateral and central nuclei of the amygdala produce differential affects on fear conditioning. *J Neurosci* 24: 7654-7662.
- Kotz C. M, Teske J. A, Levine J. A, Wang C. F., (2002).** Feeding and activity induced by orexin A in the lateral hypothalamus in rats. *Regul Pept* 104:27-32.
- Kukkonen J. P., Holmqvist T., Ammoun S., Åkerman K. E. O., (2002).** Functions of the orexinergic/hypocretinergic system. *Am J Physiol Cell Physiol* 283:C1567-C1591.
- Kumari V., Postma P., (2005).** Nicotine use in schizophrenia: the self medication hypotheses. *Neurosci Biobehav Rev.*29: 1021–1034.
- Kunii K., Yamanaka A., Nambu T., Matsuzaki I., Goto K., Sakurai T., (1999).** Orexins/hypocretins regulate drinking behaviour. *Brain Res* 842: 256-261.
- Kushikata T., Hirota K., Yoshida H., Kudo M., Lambert D. G., Smart D., Jerman J. C., Matsuki A., (2003).** Orexinergic neurons and barbiturate anesthesia. *Neuroscience* 121, 855–863. **Kent J. M., Mathew S. J., Gorman J. M. (2002).** Molecular targets in the treatment of anxiety. *Biol Psychiatry* 52:1008–1030.
- Kent J. M., Mathew S. J., Gorman J. M. (2002).** Molecular targets in the treatment of anxiety. *Biol Psychiatry* 52:1008–1030.
- Kessler R. C. (2007).** The global burden of anxiety and mood disorders: Putting the European Study of the Epidemiology of Mental Disorders (ESEMeD) findings into perspective. *J Clin Psychiatry* 68:10–19.
- Kilduff T. S., Lein Ed. S., de la Iglesia H., Sakurai T., Fu Y., Shaw P. (2008).** New Developments in Sleep Research: Molecular Genetics, Gene Expression, and Systems Neurobiology. *J Neurosci* 28(46):11814–11818.
- Kilduff T. S., Peyron C. (2000).** The hypocretin/orexin ligand– receptor system: implications for sleep and sleep disorders. *Trends Neurosci* 23:359– 365.
- Kim J. J., Diamond D. M. (2002).** The stressed hippocampus, synaptic plasticity and lost memories. *Nature Reviews Neuroscience* 3(6):453–462.
- Kirchgessner A. L., (2002).** Orexins in the brain-gut axis. *Endoc. Rev* 23:1-15.
- Kittler J. T., Moss S. J. (2003).** Modulation of GABA<sub>A</sub> receptor activity by phosphorylation and receptor trafficking: implications for the efficacy of synaptic inhibition. *Curr Opin Neurobiol* 13:341-347.
- Kiwaki K., Kotz C. M., Wang C., Lanningham-Foster L., Levi J. A. (2004).** Orexin A (hypocretin 1) injected into hypopyhalamic paraventricular nucleus and spontaneous physical activity in rats. *Am J Physiol Endocrinol Metab* 286:E551-E559.
- Kodama T., Usui S., Honda Y., Kimura M. (2005).** High Fos expression during the active phase in orexin neurons of a diurnal rodent, *Tamias sibiricus barberi*. *Peptides* 26,631–638.

- Kokare D. M., Patole A. M., Carta A., Chopde C. T., Subhedar N. K. (2006).** GABAA receptors mediate orexin-A induced stimulation of food intake. *Neuropharmacol* 50:16-24.
- Koo J. W., Han J. S., Kim J. J. (2004).** Selective neurotoxic lesions of basolateral and central nuclei of the amygdala produce differential affects on fear conditioning. *J Neurosci* 24:7654-7662.
- Korpi E. R., Gründer G., Lüddens H. (2002).** Drug interactions at GABA<sub>A</sub> receptors. *Progr Neurobiol* 67:113-159.
- Kotz C. M., Teske J. A., Levine J. A., Wang C. F. (2002).** Feeding and activity induced by orexin A in the lateral hypothalamus in rats. *Regul Pept* 104:27-32.
- Kotz C. M., Teske J. A., Thorpe A. J., Novak C. M., Kiwaki K., Levine J. A. (2006).** Orexin A mediation of time spent moving in rats neural mechanisms *Neurosci* 142,29-36.
- Koyama R., Yamada M. K., Fujisawa S., Katoh-Semba R., Matsuki N., Ikegaya Y. (2005).** Brain-derived neurotrophic factor induces hyperexcitable reentrant circuits in the dentate gyrus. *J Neurosci* 24:15-24.
- Kramer M. S., Winokur A., Kelsey J., Preskorn S. H., Rothschild A. J., Snavely D., Ghosh K., Ball W. A., Reines S. A., Munjack D., Apter J. T., Cunningham L., Kling M., Bari M., Getson A., Lee Y. (2004).** Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. *Neuropsychopharmacology* 29,385392.
- Kukkonen J.P., Holmqvist T., Ammoun S., Akerman K. E. O. (2002).** Functions of the orexinergic/hypocretinergic system. *Am J Physiol Cell Physiol* 283:1567-1591.
- Kuru M., Ueta Y., Serino R., Nakazato M., Yamamoto Y., Shibuya I., Yamashita H. (2000).** Centrally administered orexin/hypocretin activates HPA axis in rats. *NeuroReport* 11:1977–1980.
- Kuteeva E., Hokefelt T., Wardi T., Ogren S. O. (2008).** Galanin, galanin receptor subtypes and depression-like behavior. *Cell Mol Life Sci* 65,1854–1863.
- Kittler J. T., Moss S. J. (2003).** Modulation of GABA<sub>A</sub> receptor activity by phosphorylation and receptor trafficking: implications for the efficacy of synaptic inhibition. *Curr Opin Neurobiol* 13:341-347.
- Kiwaki K., Kotz C. M., Wang C., Lanningham-Foster L., Levi J. A. (2004).** Orexin A (hypocretin 1) injected into hypoyhalamic paraventricular nucleus and spontaneous physical activity in rats. *Am J Physiol Endocrinol Metab* 286:E551-E559.
- Knapska E, Nikolaev E, Boguszewski P, Walasek G, Blaszczyk J, Kaczmarek L, Werka T. (2006).** Between-subject transfer of emotional information evokes specific pattern of amygdala activation. *Proc Natl Acad Sci USA* 103:3858-3862.
- Kodama T., Usui S., Honda Y., Kimura M. (2005).** High Fos expression during the active phase in orexin neurons of a diurnal rodent, *Tamias sibiricus barberi*. *Peptides* 26,631–638.

- Kokare D. M., Patole A. M., Carta A., Chopde C. T., Subhedar N. K. (2006).** GABAA receptors mediate orexin-A induced stimulation of food intake. *Neuropharmacol* 50:16-24.
- Koo J. W., Han J. S., Kim J. J. (2004).** Selective neurotoxic lesions of basolateral and central nuclei of the amygdala produce differential affects on fear conditioning. *J Neurosci* 24:7654-7662.
- Korotkova TM, Eriksson KS, Haas HL, Brown RE.** Selective excitation of GABAergic neurons in the substantia nigra of the rat by orexin/hypocretin in vitro. *Regul Pept* 104:83-89, (2002).
- Korpi ER, Gründer G, Lüddens H. (2002).** Drug interactions at GABAA receptors. *Progr Neurobiol* 67: 113-159.
- Kotz C. M., Teske J. A., Levine J. A., Wang C. F. (2002).** Feeding and activity induced by orexin A in the lateral hypothalamus in rats. *Regul Pept* 104:27-32.
- Kotz C. M., Teske J. A., Thorpe A. J., Novak C. M., Kiwaki K., Levine J. A. (2006).** Orexin A mediation of time spent moving in rats neural mechanisms *Neurosci* 142,29-36.
- Koyama R., Yamada M. K., Fujisawa S., Katoh-Semba R., Matsuki N., Ikegaya Y. (2005).** Brain-derived neurotrophic factor induces hyperexcitable reentrant circuits in the dentate gyrus. *J Neurosci* 24:15-24.
- Kramer M. S., Winokur A., Kelsey J., Preskorn S. H., Rothschild A. J., Snavelly D., Ghosh K., Ball W. A., Reines S. A., Munjack D., Apter J. T., Cunningham L., Kling M., Bari M., Getson A., Lee Y. (2004).** Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. *Neuropsychopharmacology* 29,385392.
- Kukkonen J.P., Holmqvist T., Ammoun S., Akerman K. E. O. (2002).** Functions of the orexinergic/hypocretinergic system. *Am J Physiol Cell Physiol* 283:1567-1591.
- Kunii K, Yamanaka A, Nambu T, Matsuzaki I, Goto K, Sakurai T. (1999).** Orexins/hypocretins regulate drinking behaviour. *Brain Res* 842: 256-261,
- Kurose T, Ueta Y, Yamamoto Y, Serino R, Ozaki Y, Saito J, Nagata S, Yamashita H. (2002).** Effects of restricted feeding on the activity of hypothalamic Orexin (OX)-A containing neurons and OX2 receptor mRNA level in the paraventricular nucleus of rats. *Regul Pept* 104:145-151.
- Kuru M., Ueta Y., Serino R., Nakazato M., Yamamoto Y., Shibuya I., Yamashita H. (2000).** Centrally administered orexin/hypocretin activates HPA axis in rats. *NeuroReport* 11:1977–1980.
- Kuteeva E., Hokefelt T., Wardi T., Ogren S. O. (2008).** Galanin, galanin receptor subtypes and depression-like behavior. *Cell Mol Life Sci* 65,1854–1863.
- La Fleur S. E., Kalsbeek A., Wortel J., Fekkes M. L., Buijs R. M., (2001).** A daily rhythm in glucose tolerance: a role for the suprachiasmatic nucleus. *Diabetes* 50:1237-1243.
- Lambe E. K., Aghajanian G. K., (2003).** Hypocretin (orexin) induces calcium transients in single spines postsynaptic to identified thalamocortical boutons in prefrontal slice. *Neuron* 40, 139–150.



- Lang E. J. and Pare´ D., (1998).** Synaptic responsiveness of interneurons of the cat lateral amygdaloid nucleus. *Neuroscience* 83: 877–889.
- Lang D. J., Khorram B., Goghari V. M., Kopala L. C., Vidorpe R. A., Rui Q., Smitt G. N., Honer W. G., (2006).** Reduced anterior internal capsule and thalamic volumes in first-episode psychosis. *Schizophr Res*; 87:89–99.
- Lafleur D. L., Pittenger C., Kelmendi B., Gardner T., Wayslink S., Malison R. T., Sanacora G. S., Krystal J. H., Coric V. (2006).** N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. *Psychopharmacology* 184:254-256.
- Lambe E. K., Aghajanian G. K. (2003).** Hypocretin (orexin) induces calcium transients in single spines postsynaptic to identified thalamocortical boutons in prefrontal slice. *Neuron* 40:139-150.
- Lambe E. K., Liu R. J., Aghajanian G. K. (2007).** Schizophrenia, hypocretin (orexin), and the thalamocortical activating system. *Schizophr Bull* 33,1284–1290.
- Lang M., Bufe B., De Pol S., Reiser O., Meyerhof W., Beck-Sickingher A. G. (2006).** Structural properties of orexins for activation of their receptors. *J Pep Sci* 12:258-266.
- Ledgerwood L., Richardson R., Cranney J. (2003).** Effects of D-cycloserine on extinction of conditioned freezing. *Behavioral Neuroscience* 117:341–349.
- LeDoux J. E. (2000).** Emotion circuits in the brain. *Annu Rev Neurosci* 23,155–184.
- Lee J.-H., Bang, E., Chae K.-J., Lee D. W., Lee W. (1999).** Solution structure of a new hypothalamic neuropeptide, human hypocretin-2/ orexin-B. *Eur J Biochem* 266,831– 839.
- Lee M. G., Hassani O. K., Jones B. E. (2005).** Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle. *J Neurosci* 25:6716–20.
- Lelas S, Wong H, Li YW, Heman KL, Ward KA, Zeller KL, Sieracki KK, Polino JL., Godonis H. E., Ren S. X., Yan X. X., Arneric S. P., Robertson D. W., Hartig P. R., Grossman S., Trainor G. L., Taub R. A., Zaczek R., Gilligan P. J., McElroy J. F. (2004).** Anxiolyticlike effects of the corticotropin-releasing factor1 (CRF1) antagonist DMP904 [4-(3- pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine] administered acutely or chronically at doses occupying central CRF1 receptors in rats. *J Pharmacol Exp Ther* 309:293–302.
- Li Y., Gao X. B., Sakurai T., van den Pol A. N. (2002).** Hypocretin/orexin excites hypocretin neurons via a local glutamate neuron-A potential mechanism for orchestrating the hypothalamic arousal system. *Neuron* 36(6)1169–1181.
- Lafleur D. L., Pittenger C., Kelmendi B., Gardner T., Wayslink S., Malison R. T., Sanacora G. S., Krystal J. H., Coric V. (2006).** N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. *Psychopharmacology* 184:254-256.

- LaFleur SE, Kalsbeek A, Wortel J, Fekkes ML, Buijs RM.** A daily rhythm in glucose tolerance: a role for the suprachiasmatic nucleus. *Diabetes* 50:1237-1243, (2001).
- Lambe E. K., Aghajanian G. K. (2003).** Hypocretin (orexin) induces calcium transients in single spines postsynaptic to identified thalamocortical boutons in prefrontal slice. *Neuron* 40:139-150.
- Lambe E. K., Liu R. J., Aghajanian G. K. (2007).** Schizophrenia, hypocretin (orexin), and the thalamocortical activating system. *Schizophr Bull* 33,1284–1290.
- Lang M, Bufe B, De Pol S, Reiser O, Meyerhof W, Beck-Sickinger AG. (2006).** Structural properties of orexins for activation of their receptors. *J Pep Sci* 12:258-266.
- Lang M., Bufe B., De Pol S., Reiser O., Meyerhof W and Beck-Sickinger A. G., (2001).** Structural properties of orexins for activation of their receptors. *J Pep Sci* 12, 258–266.
- Lang P. J., Davis M, and Ohmana A., (2000).** Fear and anxiety: animal models and human cognitive psychophysiology. *J Affect Disord* 61: 137– 159.
- Lang M., Soll R. M., Durrenberger F., Dautzenberg F. M, Beck-Sickinger A. G., (2004).** Structure activity studies of orexin a and orexin B at the human orexin 1 and orexin 2 receptors led to orexin 2 receptor selective and orexin 1 receptor preferring ligands. *J Med Chem* 47:1153-1160.
- LeDoux J. E., (2000).** Emotion circuits in the brain. *Annu Rev Neurosci* 23: 155–184.
- Lerma J., (2003).** Roles and rules of kainite receptors in synaptic transmission. *Nat. Rev. Neurosci.* 4: 481-495.
- Li Y., Gao X-B., Sakurai T. and van den Pol A. N., (2002).** Hypocretin/orexin excites hypocretin neurons via a local glutamate neuron: a potential mechanism for orchestrating the hypothalamic arousal system. *Neuron.* 36:1169–1181.
- Linker R., Braune G., Schwegler H., (2000).** Differential projection of the posterior paralaminar thalamic nuclei to the amygdaloid complex in the rat. *Exp Brain Res* 134: 520–532.
- Lopez de Armentia M., and Sah P. (2003).** Development and subunit composition of synaptic NMDA receptors in the Amygdala: NR2B synapses in the adult central Amy. *The Journal of Neuroscience* 6876-6883.
- Lopez M., Soane L. M., Tovar S., Nogueiras R., Dieguez C., Senaris R., (2004).** Orexin-A regulates growth hormone-releasing hormone mRNA content in a nucleus-specific manner and somatostatin mRNA content in a growth hormone-dependent fashion in the rat hypothalamus. *Eur. J. Neurosci.* 19: 2080-2088.
- Lopez-Rodriguez F., Medina-Ceja L., Wilson C. L., Jhung D., Morales-Villagran A., (2007).** Changes in extracellular glutamate levels in rat orbitofrontal cortex during sleep and wakefulness. *Arch. Med. Res.* 38, 52–55.

- Louie K., Wilson M. A., (2001).** Temporally structured replay of awake hippocampal ensemble activity during rapid eye movement sleep. *Neuron* 29:145-156.
- Low K., Crestani F., Keist R., Benke D., Bruñig I., Benson J. A., Fritschy J. M., Rühlcke T., Bluethmann H., Möhler H., Rudolph U., (2000).** Molecular and neuronal substrate for the selective attenuation of anxiety, *Science* 290:131–134.
- Lang M., Bufe B., De Pol S., Reiser O., Meyerhof W., Beck-Sickinger A. G. (2006).** Structural properties of orexins for activation of their receptors. *J Pep Sci* 12:258-266.
- Laureys S, Peigneux P, Phillips C, Fuchs S, Degueldre C, Aerts J, Del Fiore G, Petiau C, Luxen A, Van der Linden M.** Experience-dependent changes in cerebral functional connectivity during human rapid eye movement sleep. *Neuroscience* 105:521-525, (2001).
- Le Doux J. (2007).** The amygdala. *Curr Biol* 17:R868-R874.
- Ledgerwood L., Richardson R., Cranney J. (2003).** Effects of D-cycloserine on extinction of conditioned freezing. *Behavioral Neuroscience* 117:341–349.
- LeDoux J. E. (2000).** Emotion circuits in the brain. *Annu Rev Neurosci* 23,155–184.
- Lee J.-H., Bang, E., Chae K.-J., Lee D. W., Lee W. (1999).** Solution structure of a new hypothalamic neuropeptide, human hypocretin-2/ orexin-B. *Eur J Biochem* 266,831–839.
- Lee M. G., Hassani O. K., Jones B. E. (2005).** Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle. *J Neurosci* 25:6716–20.
- Lee SH, Simonetta A, Sheng M. (2004).** Subunit rules governing the sorting of internalized AMPA receptors in hippocampal neurons. *Neuron* 43:221-236.
- Lasas S, Wong H, Li YW, Heman KL, Ward KA, Zeller KL, Sieracki KK, Polino JL., Godonis H. E., Ren S. X., Yan X. X., Arneric S. P., Robertson D. W., Hartig P. R., Grossman S., Trainor G. L., Taub R. A., Zaczek R., Gilligan P. J., McElroy J. F. (2004).** Anxiolyticlike effects of the corticotropin-releasing factor1 (CRF1) antagonist DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine] administered acutely or chronically at doses occupying central CRF1 receptors in rats. *J Pharmacol Exp Ther* 309:293–302.
- Li Y., Gao X. B., Sakurai T., van den Pol A. N. (2002).** Hypocretin/orexin excites hypocretin neurons via a local glutamate neuron-A potential mechanism for orchestrating the hypothalamic arousal system. *Neuron* 36(6)1169–1181.
- Liebsch G., Landgraf R., Engelmann M., Lorsch P., Holsboer F., (1999).** Differential behavioural effects of chronic infusion of CRH 1 and CRH 2 receptor antisense oligonucleotides into the rat brain. *J Psychiatr Res* 33,153–163.
- Liu X. H., Morris R., Spiller D., White M., Williams G. (2001).** Orexin a preferentially excites glucosesensitive neurons in the lateral hypothalamus of the rat in vitro. *Diabetes* 50:2431-2437.

- Liu R. J., van den Pol A. N., Aghajanian G. K. (2002).** Hypocretins (orexins) regulate serotonin neurons in the dorsal raphe nucleus by excitatory direct and inhibitory indirect actions. *Journal of Neuroscience* 22:9453-9464.
- Lopez J. F., Liberzon I., Vazquez D. M., Young E. A., Watson S. J. (1999).** Serotonin 1A receptor messenger RNA regulation in the hippocampus after acute stress. *Biol Psychiatry* 45 (7):934-7.
- Louis C., Stemmelin J., Boulay D., Bergis O., Cohen C., Griebel G. (2008).** Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent models. *Pharmacol Biochem Behav* 89,36–45.
- Loup F., Picard F., André V. M., Kehrli P., Yonekawa Y., Wieser H. G., Fritschy J. M. (2006).** Altered expression of  $\alpha 3$ -containing GABAA receptors in the neocortex of patients with focal epilepsy. *Brain* 129:3277–3289.
- Low K., Crestani F., Keist R., Benke D., Brunig I., Benson J. A., Fritschy J. M., Rulicke T., Bluethmann H., Mohler H., Rudolph U. (2000).** Molecular and neuronal substrate for the selective attenuation of anxiety. *Science* 290,131–134.
- Lu L., Liu D., Ceng X., Ma L. (2000).** Differential roles of corticotropin-releasing factor receptor subtypes 1 and 2 in opiate withdrawal and in relapse to opiate dependence. *European Journal of Neuroscience* 12:4398-4404.
- Lu X., Barr A. M., Kinney J. W., Sanna P., Conti B., Behrens M. M., Bartfai T. (2005).** A role for galanin in antidepressant actions with a focus on the dorsal raphe nucleus. *Proc Natl Acad Sci USA* 102:874–879.
- Lu X., Ross B., Sanchez-Alavez M., Zorrilla E. P., Bartfai T., (2008).** Phenotypic analysis of GalR2 knockout mice in anxiety- and depression-related behavioral tests. *Neuropeptides* 42,387-397.
- Lund P. E., Shariatmadari R., Uustare A., Detheux M., Parmentier M., Kukkonen, J. P., Akerman K. E. O. (2000).** The orexin OX1 receptor activates a novel calcium influx pathway necessary for coupling to phospholipase C. *J Biol Chem* 275:30806–30812.
- Lutz B. (2007).** The Endocannabinoid System and Extinction Learning. *Mol Neurobiol* 36(1):92-101.
- Liu R. J., van den Pol A. N., Aghajanian G. K. (2002).** Hypocretins (orexins) regulate serotonin neurons in the dorsal raphe nucleus by excitatory direct and inhibitory indirect actions. *Journal of Neuroscience* 22:9453-9464.
- Liu X. H., Morris R., Spiller D., White M., Williams G. (2001).** Orexin preferentially excites glucosensitve neurons in the lateral hypothalamus of the rat in vitro. *Diabetes* 50:2431-2437.
- Liu ZW, Gao XB. (2007).** Adenosine inhibits activity of hypocretin/orexin neurons by the A1 receptor in the lateral hypothalamus: a possible sleep-promoting effect. *J Neurophysiol* 97: 837-848.
- Lopez J. F., Liberzon I., Vazquez D. M., Young E. A., Watson S. J. (1999).** Serotonin 1A receptor messenger RNA regulation in the hippocampus after acute stress. *Biol Psychiatry* 45 (7):934-7

- Lopez M, Seoane L, Garcia MC, Lago F, Casanueva FF, Senaris R, Dieguez C. (2000).** Leptin regulation of prepro-orexin and orexin receptor mRNA levels in the hypothalamus. *Biochem Biophys Res Commun* 269:41-45,
- Louie K, Wilson MA. (2001).** Temporally structured replay of awake hippocampal ensemble activity during rapid eye movement sleep. *Neuron* 29:145-156.
- Louis C., Stemmelin J., Boulay D., Bergis O., Cohen C., Griebel G. (2008).** Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent models. *Pharmacol Biochem Behav* 89,36–45.
- Loup F., Picard F., André V. M., Kehrli P., Yonekawa Y., Wieser H. G., Fritschy J. M. (2006).** Altered expression of  $\alpha 3$ -containing GABAA receptors in the neocortex of patients with focal epilepsy. *Brain* 129:3277–3289.
- Low K., Crestani F., Keist R., Benke D., Brunig I., Benson J. A., Fritschy J. M., Rulicke T., Bluethmann H., Mohler H., Rudolph U. (2000).** Molecular and neuronal substrate for the selective attenuation of anxiety. *Science* 290,131–134.
- Lu L., Liu D., Ceng X., Ma L. (2000).** Differential roles of corticotropin- releasing factor receptor subtypes 1 and 2 in opiate withdrawal and in relapse to opiate dependence. *European Journal of Neuroscience* 12:4398-4404.
- Lu X., Barr A. M., Kinney J. W., Sanna P., Conti B., Behrens M. M., Bartfai T. (2005).** A role for galanin in antidepressant actions with a focus on the dorsal raphe nucleus. *Proc Natl Acad Sci USA* 102,874–879.
- Lu X., Ross B., Sanchez-Alavez M., Zorrilla E. P., Bartfai T., (2008).** Phenotypic analysis of GalR2 knockout mice in anxiety- and depression-related behavioral tests. *Neuropeptides* 42,387-397.
- Lund P. E., Shariatmadari R., Uustare A., Detheux M., Parmentier M., Kukkonen, J. P., Akerman K. E. O. (2000).** The orexin OX1 receptor activates a novel calcium influx pathway necessary for coupling to phospholipase C. *J Biol Chem* 275:30806–30812.
- Lutz B. (2007).** The Endocannabinoid System and Extinction Learning. *Mol Neurobiol* 36(1):92-101.
- Macedo C. E., Martinez R. C., Albrechet-Souza L., Molina V. A., Brandão M. L. (2007).** 5-HT<sub>2</sub>- and D1-mechanisms of the basolateral nucleus of the amygdala enhance conditioned fear and impair unconditioned fear. *Behavioural Brain Reseach* 177 (1), 100–108.
- Mahanty N. K. and Sah P., (1998).** Calcium-permeable AMPA receptors mediate long-term potentiation in interneurons in the amygdala. *Nature* 394: 683–687.
- Malendowicz L. K., Tortorella C., Nussdorfer G. G., (1999).** Orexins stimulate corticosterone secretion of rat adrenocortical cells, through the activation of the adenylate cyclase-dependent signalling cascade.
- Malenka R. C. and Nicoll R. A., (1999).** Long-term potentiation: a decade of progress? *Science* 285: 1870–1874.

- Marcus J. N., Aschkenasi C. J., Lee C. E., Chemelli R. M., Saper C. B., Yanagisawa M., Elmquist J. K., (2001).** Differential expression of orexin receptors 1 and 2 in the rat brain, *J. Comp. Neurol.* 435 6–25.
- Maren S., (1999).** Long-term potentiation in the amygdala: a mechanism for emotional learning and memory. *Trends Neurosci* 22: 561–567.
- Maren S., (2001)** Neurobiology of Pavlovian fear conditioning. *Annu Rev Neurosci* 24: 897–931.
- Martin G., Fabre V., Siggins G. R., de Lecea L., (2002).** Interaction of the hypocretins with neurotransmitters in the nucleus accumbens. *Regul. Pept.*,104: 111-117.
- Marowsky A., Fritschy J. M., Vogt K. E. (2004).** Functional mapping of GABA A receptor subtypes in the amygdala. *Eur J Neurosci* 20:1281-1289.
- Martinez G. S., Smale L., Nunez A. A. (2002).** Diurnal and nocturnal rodents show rhythms in orexinergic neurons. *Brain Res* 955,1–7.
- Mathew S. J. (2005).** Exploring glutamate function in mood and anxiety disorders; rationale and future directions. *CNS Spectr* 10:806–807.
- Mathew S. J., Prince R. B., Charney D. S. (2008).** Recent advances in the neurobiology of anxiety disorders: implications for novel therapeutics. *Am J Med Genet C Semin Med Genet* 148C(2):89-98.
- Matsuki T., Nomiya M., Takahira H., Hirashima N., Kunita S., Takahashi S., Yagami K., Kilduff T. S., Bettler B., Yanagisawa M., Sakurai T. (2008).** Selective loss of GABAB receptors in orexin-producing neurons results in disrupted sleep/wakefulness architecture. *Proc Natl Acad Sci U S A* 106(21):8790.
- Matuszczak Y., Farid M., Jones J., Lansdowne S., Smith M. A., Taylor A. A., Reid M. B. (2005).** Effects of N-acetylcysteine on glutathione oxidation and fatigue during handgrip exercise. *Muscle Nerve* 32:633–638.
- Maubach K. (2003).** GABA(A) receptor subtype selective cognition enhancers. *Curr Drug Targets CNS Neurol Disord* 2:233-239.
- Mazzocchi G., Malendowicz L. K., Gottardo L., Aragona F., Nussdorfer G. G. (2001).** Orexin A stimulates cortisol secretion from human adrenocortical cells through activation of adenylate cyclase-dependent signalling cascade. *J Clin Endocrinol Metab* 86:778-782.
- Malendowicz LK, Hochol A, Ziolkowska A, Nowak M, Gottardo L, Nussdorfer GG. (2001).** Prolonged orexin administration stimulates steroid-hormone secretion, acting directly on the rat adrenal gland. *Int J Mol Med* 7:401-404,
- Maren S, Quirk GJ. (2004).** Neuronal signalling of fear memory. *Nat Rev Neurosci* 5:844-852,
- Marowsky A, Fritschy JM, Vogt KE. (2004).** Functional mapping of GABA A receptor subtypes in the amygdala. *Eur J Neurosci* 20:1281-1289,

- Marsicano G, Wotjack CT, Azad SC, Bisogno T, Rammes G, Cascio MG, Hermann H, Tang J, Hofmann C, Zieglgänsberger W, Di Marzo V, Lutz B.** The endogenous cannabinoid system controls extinction of aversive memories. *Nature* 418:530-534, (2002).
- Martin G, Fabre V, Siggins GR, de Lecea L.** (2002). Interaction of the hypocretins with neurotransmitters in the nucleus accumbens. *Regul Pept* 104:111-117.
- Martina M., Royer S, and Pare'D.,** (1999). Physiological properties of central medial and central lateral amygdala neurons. *J Neurophysiol* 82: 1843–1854.
- Mateo Y., Fernandez-Pastor B., Meana J. J.,** (2001). Acute and chronic effects of desipramine and clorgyline on  $\alpha$ 2-adrenoceptors regulating noradrenergic transmission in the rat brain: a dual-probe microdialysis study. *Br. J. Pharmacol.* 133, 1362–1370.
- Matsumara K., Tsuchihashi T., Abe I.,** (2001). Central orexin-A augments sympathoadrenal outflow in conscious rabbits. *Hypertension* 37: 1382-1387.
- Mcdonald A. j.,** (1998). Cortical pathways to the mammalian amygdala. *Prog Brain Res* 55: 257–332.
- Mcdonald A. J. and Betette R. L.,** (2001). Parvalbumin-containing neurons in the rat basolateral amygdala: morphology and co-localization of Calbindin-D(28k). *Neuroscience* 102: 413–425.
- McEachern J. C., Shaw C. A.,** (1999). The plasticity-pathology continuum: defining a role for the LTP phenomenon. *J Neurosci Res* 58(1): 42-61.
- Mcgaugh J.,** (2002). Memory consolidation and the amygdala: a systems perspective. *Trends Neurosci* 25: 456.
- Mieda M., Williams S. C., Sinton C. M., Richardson J. A., Sakurai T., Yanagisawa M.,** (2004). Orexin neurons function in an efferent pathway of a food-entrainable circadian oscillator in eliciting foodanticipatory activity and wakefulness. *J. Neurosci.*, 24: 10493-10501.
- Mignot E., Taheri S., Nishino S.,** (2002). Sleeping with the hypothalamus: emerging therapeutic targets for sleep disorders. *Nat. Neurosci.* 5, 1071–1075.
- Mileykovskiy B. Y., Kiyashchenko, L. I. and Siegel, J. M.,** (2005). Behavioral correlates of activity in identified hypocretin/orexin neurons. *Neuron.* 46:787–798.
- Milner B., Squire L. R. and Kandel E. R.,** (1998). Cognitive neuroscience and the study of memory. *Neuron* 20: 445–468.
- Monda M., Viggiano A., Fuccio F., De Luca V.,** (2004). Clozapine blocks sympathetic and thermogenic reactions induced by Orexin A in rat. *Physiol Res* 53:507-513.
- Muller A. and Woodrufft.,** (2005). Distribution of the NMDA receptor NR3A subunits in the adult pig-tail macaque brain. *Journal chemistry Neuroanatomy* 29:152.172.
- Mullet M. A., Billington C. J., Levine A. S., Kotz C. M.,** (2000). Hypocretin 1 in the lateral hypothalamus activates key feeding-regulatory brain sites. *Neuro Report* 11:103-108.

- Muly E. C., Maddox M., Smith Y., (2003).** Distribution of mGluR1alpha and mGluR5 immunolabeling in primate prefrontal cortex, *J. Comp. Neurol.* 467 521–535.
- Muroya S., Funahashi H., Yamanaka A., Kohno D., Uramura K., Nambu T., Shibahara M., Kuramochi M., Takigawa M., Yanagisawa M., Sakurai T., Shioda S., Yada T., (2004).** Orexins (hypocretins) directly interact with neuropeptide Y, POMC and glucose-responsive neurons to regulate Ca<sup>2+</sup> signaling in a reciprocal manner to leptin: orexigenic neuronal pathways in the mediobasal hypothalamus. *Eur J Neurosci* 19: 1524–1534.
- Mutt D. J. and Malizia A. L., (2001).** New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder. *Br J Psychiatry* 179: 390–396.
- Martinez G. S., Smale L., Nunez A. A. (2002).** Diurnal and nocturnal rodents show rhythms in orexinergic neurons. *Brain Res* 955,1–7.
- Mathew S. J. (2005).** Exploring glutamate function in mood and anxiety disorders; rationale and future directions. *CNS Spectr* 10:806–807.
- Mathew S. J., Prince R. B., Charney D. S. (2008).** Recent advances in the neurobiology of anxiety disorders: implications for novel therapeutics. *Am J Med Genet C Semin Med Genet* 148C(2):89-98.
- Matsuki T., Nomiya M., Takahira H., Hirashima N., Kunita S., Takahashi S., Yagami K., Kilduff T. S., Bettler B., Yanagisawa M., Sakurai T. (2008).** Selective loss of GABAB receptors in orexin-producing neurons results in disrupted sleep/wakefulness architecture. *Proc Natl Acad Sci U S A* 106(21):8790.
- Matuszczak Y., Farid M., Jones J., Lansdowne S., Smith M. A., Taylor A. A., Reid M. B. (2005).** Effects of N-acetylcysteine on glutathione oxidation and fatigue during handgrip exercise. *Muscle Nerve* 32:633–638.
- Maubach K. (2003).** GABA(A) receptor subtype selective cognition enhancers. *Curr Drug Targets CNS Neurol Disord* 2:233-239.
- McEwen B. S. (2007).** Physiology and Neurobiology of stress and Adaption: Central Role of the Brain. *Physiol Rev* 87:873-904.
- McGaugh JL.** The amygdala modulates the consolidation of memories of emotionally arousing experiences. *Annu Rev Neurosci* 27:1-28, (2004).
- McKernan R. M., Rosahl T. W., Reynolds D. S., Sur C., Wafford K. A., Atack J. R., Farrar S., Myers J., Cook G., Ferris P., Garrett L., Bristow L., Marshall G., Macaulay A., Brown N., Howell O., Moore K. W., Carling R. W., Street L. J., Castro J. L., Ragan C. I., Dawson G. R., Whiting P. J. (2000).** Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA<sub>A</sub> receptor  $\alpha_1$  subtype. *Nat Neurosci* 3:587-592.
- McLean P. J., Shpektor D., Bandyopadhyay S., Russek S. J., Farb D. H. (2000).** A minimal promoter for the GABA<sub>A</sub> receptor  $\alpha_6$ -subunit gene controls tissue specificity. *J Neurochem* 74:1858-1869.



- Mezzogiorno V., Esposito V., Papa M., Passatore C., Valentino B. (1999).** Testo e atlante di anatomia umana. Piccin
- Micale V., Tamburella A., Leggio G. M., Mazzola C., Li Volsi V., Drago F. (2008).** Behavioral effects of saredutant, a tachykinin NK2 receptor antagonist, in experimental models of mood disorders under basal and stress-related conditions. *Pharmacol Biochem Behav* 90,463–469.
- Mignont E, Lammers GJ, Ripley B, Neusimalova S, Overseem S, Vankova J, Black J, Harsh S, Bassetti C, Schrader H, Nishino S.** The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. *Arch Neurol* 59:1553-1563, (2002).
- Milad M. R., Quirk G. J. (2002).** Neurons in medial prefrontal cortex signal memory for fear extinction. *Nature* 420:70–74.
- Mileykovskiy B. Y., Kiyashchenko L. I., Siegel J. M. (2005).** Behavioral correlates of activity in identified hypocretin/orexin neurons. *Neuron* 46:787–798.
- Millan M. J., Brocco M., Gobert A., Dorey G., Casara P., Dekeyne A. (2001).** Anxiolytic properties of the selective, non-peptidergic CRF(1) antagonists, CP154,526 and DMP695: a comparison to other classes of anxiolytic agent. *Neuropsychopharmacology* 25:585–600.
- Mineka S., Ohman A. (2002).** Phobias and preparedness: the selective, automatic and encapsulate nature of fear. *Biol Psychiatry* 52 (10):927-937.
- Miranda M. I., LaLumiere R. T., Buen T. V., Bermudez-Rattoni F., McGaugh J. L. (2003).** Blockade of noradrenergic receptors in the basolateral amygdale impairs taste memory. *Eur J Neurosci* 18:2605–2610.
- Mitsukawa K., Lu X., Bartfai T. (2008).** Galanin, galanin receptors and drug targets. *Cell Mol Life Sci* 65,1796–1805.
- Mitsukawa K., Mombereau C., Lotscher E., Uzunov D. P., van der Putten H., Flor P. J., Cryan F. J. (2006).** Metabotropic glutamate receptor subtype 7 ablation causes dysregulation of the HPA axis and increases hippocampal BDNF protein levels: implications for stress related psychiatric disorders. *Neuropsychopharmacol* 31:1112–1122.
- Modirrousta M, Mainville L, Jones BE.** Orexin and MCH neurons express c-fos differently after sleep deprivation vs. Recovery and bear different adrenergic receptors. *Eur J Neurosci* 21:2807-2816, (2005).
- Mohler H. (2006).** GABA<sub>A</sub> receptor diversity and pharmacology. *Cell Tissue Res* 326(2):505-16.
- Morgane P. J., Galler J. R., Mokler D. J. (2005).** A review of systems and networks of the limbic forebrain/limbic midbrain. *Prog Neurobiol* 75:143–160.
- Morin L.P., Wood R. I. (2000).** A stereotaxic Atlas of the Golden Hamster Brain. *Elsevier*, New York.
- Moss S. J., Smart T. G. (2001).** Constructing inhibitory synapses. *Nat Rev Neurosci* 2:240-250.

- Mullet MA, Billington CJ, Levine AS, Kotz CM. (2000).** Hypocretin 1 in the lateral hypothalamus activates key feeding-regulatory brain sites. *Neuro Report* 11:103-108.
- Muroya S, Uramura K, Sakurai T, Takigawa M, Yada T. (2001).** Lowering glucose concentrations increases cytosolic Ca<sup>2+</sup> in orexin neurons of the rat lateral hypothalamus. *Neurosci Lett* 309:165- 8.
- Muroya S, Funahashi H, Yamanaka A, Kohno D, Uramura K, Nambu T, Shibahara M, Kuramochi M, Takigawa M, Yanagisawa M, Sakurai T, Shioda S, Yada T. (2004).** Orexins (Hypocretins) directly interact with neuropeptide Y, POMC and glucose- responsive neurons to regulate Ca<sup>2+</sup> signaling in a reciprocal manner to leptin: orexigenic neuronal pathways in the mediobasal hypothalamus. *Eur J Neurosci* 19(6)1524-1534.
- Nader K, Majidishad P, Amorapanth P, LeDoux J. E. (2001).** Damage to the Lateral and Central, but Not Other, Amygdaloid Nuclei Prevents the Acquisition of Auditory Fear Conditioning. *Learn Mem* 8(3):156-63.
- Nakabayashi M, Suzuki T, Takahashi K, Muramatsu Y, Kaneko C, Date F, Takeyama J, Darnel A. D., Moriya T., Sasano H. (2003).** Orexin-A expression in human peripheral tissues. *Mol Cell Endocrinol* 205:43-50.
- Nakajima M, Inui A, Asakawa A, Momose K, Ueno N, Teranishi A, Baba S, Kasuga M. (1998).** Neuropeptide Y produces anxiety via Y2-type receptors. *Peptides* 19,359–363.
- Nakamura T, Uramura K, Nambu T, Yada T, Goto K, Yanagisawa M, Sakurai T. (2000).** Orexin-induced hyperlocomotion and stereotypy are mediated by the dopaminergic system. *Brain Res* 873 (1) 181–187.
- Nakazato M.** Distribution of orexin/hypocretin in the rat median eminence and pituitary. *Brain Res Mol Brain Res* 76:1-6, (2000b).
- Nambu T, Sakurai T, Mizukami K, Hosoya Y, Yanagisawa M, Goto K.** Distribution of orexin neurons in the adult rat brain. *Brain Res* 827:243-260, (1999).
- Narita M, Nagumo Y, Hashimoto S, Narita M, Khotib, J., Miyatake M, Sakurai T, Yanagisawa M, Nakamachi T, Shioda S, Suzuki T. (2006).** Direct involvement of orexinergic systems in the activation of the mesolimbic dopamine pathway and related behaviors induced by morphine. *J. Neurosci* 26:398–405.
- Naslund E., Ehrstrom M., Ma J., Hellstrom P. M., Kirchgessner A. L. (2002).** Localization and effects of orexin on fasting motility in the rat duodenum. *Am J Physiol Gastrointest Liver Physiol* 282:G470-G479.
- Nestadt G., Samuels J., Riddle M., Bienvenu 3rd., O. J., Liang K. Y., LaBuda M., Walkup J., Grados M., Hoehn-Saric R. (2000).** A family study of obsessive–compulsive disorder. *Arch. Gen. Psychiatry* 57 (4),358–363.
- Nicoll R. A., (2003).** Expression mechanisms underlying long-term potentiation; a postsynaptic view. *Philos Trans R Sol Lond B Biol Sci* 358:721-726.

- Niimi M., Sato M., Taminato T., (2001).** Neuropeptide Y in central control of feeding and interactions with orexin and leptin. *Endocrine* 14: 269–273.
- Nikisch G., Agren H., Eap C. B., Czernik A., Baumann P., Mathé A. A. (2005).** Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram. *Int. J. Neuropsychopharmacol* 8,403–410.
- Nishino S. (2001).** Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities. *Eur J Neurosci* 14:1075-1081.
- Nixon J. P. and Smale L., (2007).** A comparative analysis of the distribution of immunoreactive orexin A and B in the brains of nocturnal and diurnal rodents. *Behav Brain Funct*, 3, 3-28.
- Noebels, J. L. (2003).** The biology of epilepsy genes. *Annu. Rev. Neurosci* 26:599–625.
- Novak C. M., Kotz C. M., Levine J. A. (2006).** Central orexin sensitivity, physical activity, and obesity in diet-induced obese and diet-resistant rats. *Am J Physiol Endocrinol Metab* 290:E396-E403.
- Nowend K. L., Arizzi M., Carlson B. B., Salamone J. D., (2001).** D1 or D2 antagonism in nucleus accumbens core or dorsomedial shell suppresses lever pressing for food but leads to compensatory increases in chow consumption. *Pharmacology Biochemistry and Behavior* 69 (3–4), 373–382.
- Núñez A., Rodrigo-Angulo M. L., De Andrés I., Garzón M. (2009).** Hypocretin /Orexin Neuropeptides: Participation in the Control of Sleep-Wakefulness Cycle and Energy Homeostasis. *Current Neuropharmacology* 7,50-59.
- O’Hara B. F., Watson F. L., Srere H. K., Kumar H., Wiler S. W., Welch S. K., Bitting L., Heller H. C., Kilduff T. S., (1999).** Gene expression in the brain across the hibernation cycle. *J Neurosci* 19:3781-3790.
- Ogren S. O., Kuteeva E., Hökfelt T., Kehr J. (2006).** Galanin receptor antagonists: a potential novel pharmacological treatment for mood disorders. *CNS Drugs* 20,633–635.
- Ogren S. O., Razani H., Elvander-Tottie E., Kehr J. (2007).** The neuropeptide galanin as an in vivo modulator of brain 5-HT<sub>1A</sub> receptors: possible relevance for affective disorders. *Physiol Behav* 92,172–179.
- Ohkubo T., Boswell T., Lumineau S., (2002)** Molecular cloning of chicken prepro-orexin cDNA and preferential expression in the chicken hypothalamus. *Biochim Biophys Acta* 1577: 476-480.
- Ohkubo T., Tsukada A., Shamoto K., (2003).** cDNA cloning of chicken orexin receptor and tissue distribution: sexually dimorphic expression in chicken gonads. *J. Mol. Endocrinol.* 31: 499-508.
- Ohkubo T, Boswell T, Lumineau S. (2002).** Molecular cloning of chicken prepro-orexin cDNA and preferential expression in the chicken hypothalamus. *Biochim Biophys Acta* 1577: 476-480,
- Ohno K. and Sakurai T., (2008).** Orexin neuronal circuitry: role in the regulation of sleep and wakefulness. *Frontiers Neuroendocrin.*, 29: 70-87.

- Okano S., Nagaya H., Ikeura Y., Natsugari H., Inatomi N. (2001).** Effects of TAK-637, a novel neurokinin-1 receptor antagonist, on colonic function in vivo. *J Pharmacol Exp Ther* 298,559–564.
- Okumura T., Takeuchi S., Motomura W., Yamada H., Egashira S. I. S., Asahi S., Kanatani A., Ihara M., Kohgo Y., (2001).** Requirement of intact disulfide bonds in orexin-A-induced stimulation of gastric acid secretion that is mediated by OX1 receptor activation. *Biochem. Biophys. Res. Commun.* 280: 976-981.
- Olsen R. W., Sieghart W. (2008).** International Union of pharmacology. LXX. Subtypes of  $\gamma$ -Aminobutyric Acid<sub>A</sub> Receptors: Classification on the Basis OF Subunit Composition,
- Olsen R. W., Sieghart W. (2009).** GABA<sub>A</sub> receptors: subtypes provide diversity of function and pharmacology. *Neuropharmacology* 56:141-148
- Opthof T., Rook M. B., (2000).** The hibernators heart: nature's response to arrhythmogenesis? *Cardiovasc Res* 47:6-8.
- Ortiz JP, Heinricher MM, Selden NR. (2007).** Noradrenergic agonist administration into the central nucleus of the amygdala increases the tail-flick latency in lightly anesthetized rats. *Neuroscience* 148:737-743.
- Osborne P. G., Hashimoto M., (2003).** State-dependent regulation of cortical blood flow and respiration in hamsters: response to hypercapnia during arousal from hibernation. *J Physiol* 54
- Palchadhuri M. R., Hauger R. L., Wille S., Fuchs E., Dautzenberg F. M. (1999).** Isolation and pharmacological characterization of two functional splice variants of corticotropin-releasing factor type 2 receptor from *Tupaia belangeri*. *J Neuroendocrinol* 11,419-428.
- Paoletti R., Nicosia S., Clementi F., Fumagalli G. (2004).** *Farmacologia generale e molecolare*. Terza edizione, UTET.
- Pare' D., Quirk G. J., Ledoux J.E. (2004).** New vistas on amygdala networks in conditioned fear. *Journal of Neurophysiology* 92:1–9.
- Parè D. and Collins D. R., (2000).** Neuronal correlates of fear in the lateral amygdala: multiple extracellular recordings in conscious cats. *J Neurosci* 20: 2701–2710.
- Parkinson JA, Crofts HS, McGuigan M, Tomic DL, Everitt BJ, Roberts AC. (2001).** The role of the primate amygdala in conditioned reinforcement. *J Neurosci* 21:7770-7780.
- Paxinos G., Watson C. (1998).** The rat brain in stereotaxic coordinates. II ed. *Academic Press*: San Diego
- Peever J., Lai Yuan-Yang., Siegel J. M., (2003).** Excitatory effects of hypocretin-1 (orexin-A) in the trigeminal motor nucleus are reversed by NMDA antagonist. *J. Neurophysiol.* 89, 2591–2600.
- Peng Z., Hauer B., Mihalek R. M., Homanics G. E., Sieghart W., Olsen R. W., Houser C. R. (2002).** GABA<sub>A</sub> receptor subunit changes in  $\delta$  subunit-deficient mice: altered expression of  $\delta 4$  and  $\delta 2$  subunits in the forebrain. *J Comp Neurol* 446:179-197.

- Petralia R. S., Rubio M. E., Wang Y. X., (2002).** Differential distribution of glutamate receptors in the cochlear nuclei. *Hear. Res.* 147: 59-69
- Petrovich G. D., Canteras N. S., Swanson L. W., (2001).** Combinatorial amygdalar inputs to hippocampal domains and hypothalamic behaviour systems. *Brain Res Rev* 38:247-289.
- Petrovich G. D., Setlow B., Holland P. C., Gallagher M., (2002).** Amygdalo-hypothalamus circuits allows learned cues to override satiety and promote eating. *J Neurosci* 22:8748-8753.
- Peyron C., Faraco J., Rogers W., Ripley B., Overeem S., Charnay Y., Nevsimalova S., Aldrich M., Reynolds D., Albin R., Li R., Hungs M., Pedrazzoli M., Padigaru M., Kucherlapati R., Nishino S., Mignot E., (2000).** A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. *Nat. Med.*6: 991-997.
- Pitkanen A., (2000).** Connectivity of the rat amygdaloid complex. In: *The Amygdala: A Functional Analysis*, edited by Aggleton JP. Oxford, UK: Oxford Univ. Press, p. 31–115.
- Pitkanen A, Jolkkonen E, Kempainen S.** Anatomic heterogeneity of the rat amygdaloid complex. *Folia Morphol* 59:1-23, (2000).
- Pirker S, Schwarzer C, Wieselthaler A, Sieghart W, Sperk G.** GABA<sub>A</sub> receptors: immunocytochemical distribution of 13 subunits in the adult rat brain. *Neuroscience* 101: 815-850, (2000).
- Pitts M. W., Todorovic C., Blank T., Takahashi L. K. (2009).** The central nucleus of the amygdala and corticotropin-releasing factor: insight into contextual fear memory. *The Journal of Neuroscience* 29(22):7379-7388.
- Place N. J., Veloso C., Visser G. H., Kenagy G. J., (2002).** Energy expenditure and testosterone in free-living male yellow-pine chipmunks. *J Exp Zool* 292:460-467.
- Plaza-Zabala A., Martín-García E., de Lecea L., Maldonado R., Berrendero F. (2010).** Hypocretins regulate the anxiogenic-like effects of nicotine and induce reinstatement of nicotine-seeking behavior. *J Neurosci* 30(6):2300-10.
- Podhorna J., Franklin K. B. (2000).** Pontine tegmentum lesions increase anxiety-like behavior in rats: a comparison with anxiety produced by beta-CCE. *Pharmacol Biochem Behav* 65,267–273.
- Price JL.** Comparative aspects of amygdala connectivity. *Ann NY Acad Sci* 985:50-58, (2003). *Progr Neurobiol* 67:113-159.
- Puelles L., (2001).** Thoughts on the development, structure and evolution of the mammalian and avian telencephalic pallium. *Philos Trans R Soc Lond B Biol Sci* 356: 1583–1598.
- Purves D., Augustine G. J., Katz L. C., La Mantia A. S., McNamara J. O., Williams S. M., (2004).** Neuroscience. *Zanichelli editore Sec. Ediz.* (2004).
- Quirk G. J., Gehlert D. R. (2003).** Inhibition of the amygdala: Key to pathological states? *Ann NY Acad Sci* 985:263–272.

**Rajarao S. J., Platt B., Sukoff S. J., Lin Q., Bender C. N., Nieuwenhuijsen B. W., Ring R.H., Schechter L. E., Rosenzweig-Lipson S., Beyer C. E. (2007).** Anxiolytic-like activity of the non-selective galanin receptor agonist, galnon. *Neuropeptides* 41:307–320.

**Randeva H. S., Karteris E., Grammatopoulos D., Hillhouse E. W., (2001).** Expression of orexin-A and functional orexin type 2 receptors in the human adult adrenals: implications for adrenal function and energy homeostasis. *J. Clin. Endocrinol. Metab.* 86: 4808-4813.

**Rang H. P., Dale M. M., Ritter J. M. (1998).** *FARMACOLOGIA* prima edizione.

**Rasia-Filho A. A., Londero R. G., Achaval M. (2000).** Functional activities of the amygdala: an overview. *J Psychiatry Neurosci* 25:14–23.

**Rasmusson A. M., Hauger R. L, Morgan C. A., Bremner J. D., Charney D. S., Southwick S. M. (2000).** Low baseline and yohimbine-stimulated plasma neuropeptide Y (NPY) levels in combat-related PTSD. *Biol Psychiatry* 47:526–539.

**Rasmussen K., Hsu M. A., Yang Y., (2007).** The Orexin-1 receptor antagonist SB-334867 blocks the effects of antipsychotics on the activity of A9 and A10 dopamine neurons: implications for antipsychotic therapy. *Neuropsychopharmacology*; 32: 786–92.

**Rattiner LM, Davis M, French CT and Ressler KJ.** Brain-derived neurotrophic factor and tyrosine kinase receptor B involvement in amygdala-dependent fear conditioning. *J Neurosci* 24:4796-4806, (2004).

**Reul J. M., Holsboer F. (2002).** Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. *Curr Opin Pharmacol* 2,23–33.

**Reynolds D.S., Rosahl T. W., Cirone J., O' Meara G. F., Haythornthwaite A., Newman R. J., Myers J., Sur C., Howell O., Rutter A. R., Atack J., Macaulay A. J., Hadingham K. L., Hutson P. H., Belelli D., Lambert J. J., Dawson G. R., McKernan R., Whiting P. J., Wafford K. A. (2003).** Sedation and anesthesia mediated by distinct GABA (A) receptor isoforms. *J Neurosci* 23:8608-8617.

**Richardson JA, Kozlowski GP, Wilson S, Arch JR, Buckingham RE, Haynes AC, Carr SA, Annan RS, McNulty DE, Liu WS, Terrett JA, Elshourbagy NA, Bergsma DJ, Yanagisawa M.** Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. *Cell* 92:573-585, (1998).

**Rieger M., Mayer G., Gauggel S., (2003).** Attention deficits in patients with narcolepsy. *Sleep.* 26:36–43.

**Ring R. H., Schechter L.E., Leonard S. K., Dwyer J. M., Platt B. J., Graf R., Grauer S., Pulicchio C., Resnick L., Rahman Z., Sukoff Rizzo S. J., Luo B., Beyer C. E., Logue S. F., Marquis K. L., Hughes Z. A., Rosenzweig-Lipson S. (2009).** Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor antagonist. *Neuropharmacology (Epub ahead of print)*.

**Rodrigues S. M., Schafe G. E. and Ledoux J. E., (2001).** Intra-amygdala blockade of the NR2B subunit of the NMDA receptor disrupts the acquisition but not the expression of fear conditioning. *J Neurosci* 21: 6889–6896.

- Rolls E. T., (1999).** The Brain and Emotion. *New York: Oxford Univ. Press*
- Rojer S., Martina M, and Pare'D., (2000).** Bistable behavior of inhibitory neurons controlling impulse traffic through the amygdala: role of a slowly deinactivating K<sub>v</sub> current. *J Neurosci* 20: 9034–9039.
- Rojer S., Martina M, and Pare'D., (2000).** Polarized synaptic interactions between intercalated neurons of the amygdala. *J Neurophysiol* 83: 3509–3518.
- Roosendaal B. (2003).** Systems mediating acute glucocorticoid effects on memory consolidation and retrieval. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* 27:1213–1223.
- Rosenkranz J. A., Grace A. A. (2002).** Cellular mechanisms of infralimbic and prelimbic prefrontal cortical inhibition and dopaminergic modulation of basolateral amygdala neurons in vivo. *The Journal of Neuroscience* 22:324–337.
- Rosenkranz J. A. and Grace A. A., (2002).** Dopamine-mediated modulation of odour-evoked amygdala potentials during pavlovian conditioning. *Nature* 417: 282–287.
- Rosenquist N, Jakobsson J, Lundberg C.** Inhibition of chromatin condensation prevents transgene silencing in a neural progenitor cell line transplanted to the rat brain. *Cell Transplant* 14:129-138, (2005).
- Rosin C., Bates T.E. and Skaper S.D, (2004).** Excitatory amino acid induced oligodendrocyte cell death in vitro: receptor-dependent and -independent mechanisms. *J. Neurochem.* 90: 1173.
- Rosin D. L., Weston M. C., Sevigny C. P., Stornetta R. L., Guyenet P. G., (2003).** Hypothalamic orexin (hypocretin) neurons express vesicular glutamate transporters VGLUT1 or VGLUT2. *J Comp Neurol* 465: 593– 603.
- Rothbaum B. O., Davis M. (2003).** Applying learning principles to the treatment of post-trauma reactions. *Ann NY Acad Sci* 1008:112–121.
- Royer S., Paré D. (2002).** Bidirectional synaptic plasticity in intercalated amygdala neurons and the extinction of conditioned fear responses. *Neuroscience* 115:455–462.
- Royer S., Martina M, and Parè D., (1999).** An inhibitory interface gates impulse traffic between the input and output stations of the amygdala. *J Neurosci* 19: 10575–10583.
- Ruby N. F., Dark J., Burns D. E., Heller H. C., Zucker I., (2002).** The suprachiasmatic nucleus is essential for circadian body temperature rhythms in hibernating ground squirrels. *J Neurosci* 22:357-364.
- Ruby N. F., (2003).** Hibernation: when good clocks go cold. *J Biol Rhythms* 18:275-286.
- Rudolph U., Crestani F., Benke D., Brunnig I, Benson J. A., Fritschy J. M., Martin J. R., Bluethmann H., Mohler H., (1999).** Benzodiazepine actions mediated by specific g-aminobutyric acidA receptor subtypes, *Nature* 401- 796– 800 .
- Rudolph U., Mohler H. (2004).** Analysis of GABAA receptor function and dissection of the pharmacology of benzodiazepines and general anesthetics through mouse genetics. *Annu Rev Pharmacol Toxicol* 44:475–498. [PubMed: 14744255].

**Russell S. H., Kim M. S., Small C. J., Abott C. R., Morgan D. G. A., Taheri S., Murphy K. G., Todd J. F., Ghatei M. A., Bloom S. R. (2000).** Central administration of orexin-A suppresses basal and domperidone stimulated plasma prolactin. *J Neuroendocrinol* 12:1213–1218.

**Russell SH, Small CJ, Dakin CL, Abbott CR, Morgan DG, Ghatei MA, Bloom SR.** The central effects of orexin-A in the hypothalamic-pituitary-adrenal axis in vivo and in vitro in male rats. *J Neuroendocrinol* 13:561-566, (2001).

**Rutter M., Silberg J. (2002).** Gene-environment interplay in relation to emotional and behavioral disturbance. *Annu Rev Psychol* 53,463–490.

**Ryuji Tosea., Tetsuya Kushikataa., Hitoshi Yoshidaa., Mihoko Kudoa., Kenichi Furukawab., Shinya Uenoc., Kazuyoshi Hirotaa., (2008).** Interaction between orexinergic neurons and NMDA receptors in the control of locus coeruleus-cerebrocortical noradrenergic activity of the rat. *Hiroaki* 036-8562.

**Sah P., Faber E. S., Lopez De Armentia M., Power J., (2003).** The amygdaloid complex: anatomy and physiology. *Physiol Rev* 83:803-834.

**Saha S., Batten T. F. and Henderson Z. A., (2000).** GABAergic projection from the central nucleus of the amygdala to the nucleus of the solitary tract: a combined anterograde tracing and electron microscopic immunohistochemical study. *Neuroscience* 99: 613–626.

**Sajdyk T. J., Fitz S. D., Shekhar A. (2006).** The role of neuropeptide Y in the amygdale on corticotropin-releasing factor receptor-mediated behavioral stress responses in the rat. *Stress* 9,21–28.

**Sajdyk T. J., Johnson P. L., Leitermann R. J., Fitz S. D., Dietrich A., Morin M., Gehlert D. R., Urban J. H., Shekhar A. (2008).** Neuropeptide Y in the amygdala induces long-term resilience to stress-induced reductions in social responses but not hypothalamic–adrenal–pituitary axis activity or hyperthermia. *J Neurosci* 28,893–903.

**Sajdyk T. J., Schober D. A., Gehlert D. R. (2002).** Neuropeptide Y receptor subtypes in the basolateral nucleus of the amygdale modulate anxiogenic responses in rats. *Neuropharmacology* 43:1165-1172.

**Sakurai T, Moriguchi T, Furuya K, Kajiwara N, Nakamura T, Yanagisawa M, Goto K.** Structure and function of human prepro-orexin gene. *J Biol Chem* 274:17771-17776, (1999).

**Sakurai T. (2005).** Roles of orexin/hypocretin in regulation of sleep/wakefulness and energy homeostasis. *Sleep Medicine Reviews* 9:231-241.

**Sakurai T. (2007).** The neural circuit of orexin (hipocretin): maintaining sleep and wakefulness. *Nat Rev Neurosci* 8:171-181.

**Sakurai T.** Roles of orexins in regulation of feeding and wakefulness. *Neuroreport* 13: 987-995, (2002).

**Sakurai T., Amemiya A., Ishii M., Matsuzaki I., Chemelli R. M., Tanaka H., Williams S. C., Richardson J. A., Kozlowski G. P., Wilson S., Arch J. R., Buckingham R. E., Haynes A. C., Carr S. A., Annan R. S., McNulty D. E., Li W. S., Terrett J. A., Elshourbagy N. A., Bergsma D. J.,**



**Yanagisawa M. (1998).** Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. *Cell* 92(5):1.

**Sams-Dodd F. (1999).** Phencyclidine in the social interaction test: an animal model of schizophrenia with face and predictive validity. *Rev Neurosci* 10(1):59-90.

**Samson RD, Parè D.** Activity-dependent synaptic plasticity in the central nucleus of the amygdala. *J Neurosci* 25:1847-1855, (2005).

**Samson W. K., Taylor M. M., Follwell M., Ferguson A. V. (2002).** Orexin actions in hypothalamic paraventricular nucleus: physiological consequences and cellular correlates. *Regul Pept* 104,97-103

**Samson WK, Taylor MM, Anderson JW, Ferguson AV.** Orexin inhibition of CRHstimulated ACTH secretion: possible role of potassium channel activation (Abstract). *Proc Ann Mtg Endocr Soc* (no. OR57-5), (2002).

**Sanchez M. M., Young L. J., Plotsky P. M., Insel T. R. (1999).** Autoradiographic and in situ hybridization localization of corticotropin-releasing factor 1 and 2 receptors in nonhuman primate brain. *J Comp Neurol* 408,365– 377.

**Sanchez de Miguel M. J., Burrell M. A., (2002).** Immunocytochemical detection of orexin A in endocrine cells of developing mouse gut. *J. Histochem Cytochem* 50: 63-70.

**Sanford LD, Parris B, Tang X.** GABAergic regulation of the central nucleus of the amygdala: implications for sleep control. *Brain Res* 956:276-284, (2002).

**Santarelli L., Gobbi G., Debs P. C., Sibille E. T., Blier P., Hen R., Heath M. J. (2001).** Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function. *Proc Natl Acad Sci USA* 98,1912–1917.

**Saper C. B., Cano G., Scammell T. E., (2005).** Homeostatic, circadian and emotional regulation of sleep. *J Comp Neurol* 493: 92-98.

**Saper CB, Chou TC, Scammell TE.** The sleep switch: hypothalamic control of sleep and wakefulness. *Trends Neurosci* 24:726-731, (2001).

**Saulskaya N. B., Mikhailova M. O., (2002).** Feeding-induced decrease in extracellular glutamate level in the rat nucleus accumbens: dependence on glutamate uptake. *Neurosci.* 112: 791-801.

**Savaskan E., Muller-Spahn F., Meier F., Wirz-Justice A., Meyer P., (2004).** Orexins and their receptors in the human retina. *Pathobiology*.7: 211-216.

**Scammell T. E., Saper C. B. (2005).** Orexin, drugs and motivated behaviors. *Nat Neurosci* 8:1286–1288.

**Scantamburlo G., Hansenne M., Fuchs S., Pitchot W., Maréchal P., Pequeux C., Anseau M., Legros J. J. (2007).** Plasma oxytocin levels and anxiety in patients with major depression. *Psychoneuroendocrinology* 32,407–410.

**Schiapparelli L., Simòn A. M., Del Rio J., Frechilla D., (2006).** Opposing effects of AMPA and 5-HT1A receptor blockade on passive avoidance and object recognition performance: correlation with AMPA receptor subunit expression in rat hippocampus. *Neuropharmacology*; 50:897–907.

**Schwartz M. W., Woods S. C., Porte D. J., Seeley Jr R., Baskin D. G., (2000).** Central nervous system control of food intake. *Nature*; 404:661–71.

**Scott K. M., Bruffaerts R., Tsang A., Ormel J., Alonso J., Angermeyer MC, Benjet C, Bromet E., de Girolamo G., de Graaf R., Gasquet I., Gureye O., Haro J. M., He Y., Kessler R. C., Levinson D., Mneimneh Z. N., Oakley Browne M. A., Posada-Villa J., Stein D. J., Takeshima T., Von Korff M. (2007).** Depression-anxiety relationships with chronic physical conditions: Results from the World Mental Health surveys. *J Affect Disord* 103:113–120.

**Selbach O., Doreulee N., Bohla C., Eriksson K. S., Sergeeva O. A., Poelchen W., Brown R. E., Haas H. L., (2004).** Orexins/hypocretins cause sharp wave and theta-related synaptic plasticity in the hippocampus via glutamatergic, gabaergic, noradrenergic, and cholinergic signaling. *Neuroscience*; 127:519–28.

**Selbach O., Bohla C., Barbara A., Doreulee N., Eriksson K. S., Sergeeva O. A., Haas H. L. (2010).** Orexins/hypocretins control bistability of hippocampal long-term synaptic plasticity through co-activation of multiple kinases. *Acta Physiol* 198,277–285.

**Shekhar A and Keim S. R., (2000).** LY354740, a potent group II metabotropic glutamate receptor agonist, prevents lactate-induced panic-like response in panic-prone rats. *Neuropharmacology* 39: 1139-1146.

**Shi C. D., Cassell M. D. (1997).** Cortical, talami and amygdaloid projections of rat temporal cortex. *J Comp Neurol* 382:153-175.

**Shi C. D., Cassell M. D. (1998).** Cascade projections from somatosensory cortex to the rat basolateral amygdala via the parietal insular cortex. *J Comp Neurol* 399:469-491.

**Shin L. M., Whalen P. J., Pitman R. K., Bush G., Macklin M. L., Lasko N. B., Orr S. P., McNerney S. C., Rauch S. L. (2001).** An fMRI study of anterior cingulate function in posttraumatic stress disorder. *Biol Psychiatry* 50:932-942.

**Shi C. and Davis M., (2001).** Visual pathways involved in fear conditioning measured with fear-potentiated startle: behavioral and anatomic studies. *J Neurosci* 21: 9844–9855.

**Shi C. J. and Cassell M. D., (1999).** Perirhinal cortex projections to the amygdaloid complex and hippocampal formation in the rat. *J Comp Neurol* 406: 299–328.

**Shiraishi T., Oomura Y., Sasaki K., Wayner M. J., (2000).** Effects of leptin and orexin-A on food intake and feeding related hypothalamic neurons. *Physiol Behav* 71: 251–261.

**Siegel JM.** Clues to the functions of mammalian sleep. *Nature* 437:1264-1271, (2005).

**Sieghart W, Sperk G.** Subunit composition, distribution and function of GABA (A) receptor subtypes. *Curr Top Med Chem* 2:795-816, (2002).

- Sieghart W., Ernst M., Bruckner S., Boresch S. (2005).** Comparative models of GABAA receptor extracellular and transmembrane domains: important insights in pharmacology and function. *Mol Pharmacol* 68(5):1291-300.
- Siegle G. J., Konecky R. O., Thase M. E., Carter C. S. (2003).** Relationships between amygdala volume and activity during emotional information processing tasks in depressed and never-depressed individuals: An fMRI investigation. *Ann NY Acad Sci* 985:481–484.
- Silva R. C. B., Ana Carolina Gargaro., Brandao M. L., (2003).** Differential regulation of the expression of contextual freezing and fear-potentiated startle by 5-HT mechanisms of the median raphe nucleus. *Laboratorio de psicobiologia, FFCLRP, campus USP, Av. Bandeirantes 3900, Ribeirao Preto 14040-901, SP, Brazil.*
- Simon J, Wakimoto H, Fujita N, Lalande M, Barnard EA.** Analysis of the set of GABAA receptor genes in the human genome. *J Biol Chem* 279:41422-41435, (2004).
- Smith B. N., Davis S. F., van Den Pol A. N., Xu W. (2002a).** Selective enhancement of excitatory synaptic activity in the rat nucleus tractus solitarius by hypocretin 2. *Neuroscience* 115:707–714.
- Smith P. M., Connolly B. C., Ferguson A. V. (2002b).** Microinjection of orexin into the rat nucleus tractus solitarius causes increases in blood pressure. *Brain Res* 950:261–267.
- Smith P. W., Dawson L. A. (2008).** Neurokinin 3 (NK3) receptor modulators for the treatment of psychiatric disorders. *Recent Pat CNS Drug Discov* 3,1–15.
- Smoller J. W., Yamaki L. H., Fagerness J. A., Biederman J., Racette S., Laird N. M., Kagan J., Snidman N., Faraone S. V., Hirshfeld-Becker D., Tsuang M. T., Slaugenhaupt S. A., Rosenbaum J. F., Sklar P. B. (2005).** The corticotropin-releasing hormone gene and behavioral inhibition in children at risk for panic disorder. *Biol Psychiatry* 57:1485–1492.
- Soderpalm A. H., Berridge K. C. (2000).** Food intake after diazepam, morphine or muscimol: microinjections in the nucleus accumbens shell. *Pharmacology Biochemistry and Behavior* 66:429-434.
- Soffin EM, Evans ML, Gill CH, Harries MH, Benham CD, Davies CH. (2002).** SB-334867-A antagonists orexin mediated excitation in the locus coeruleus. *Neuropharmacology* 42:127-133.
- Soll R., Beck-Sickinger A. G. (2000).** On the synthesis of orexin-A: anovel one-step procedure to obtain peptides with two intramolecular disulphide bonds. *J Pept Sci* 6:387– 397.
- Song C, Chen X, Xia J, Yu Z, Hu Z.** Modulatory effects of hypocretin-1/orexin-A with glutamate and  $\gamma$ -aminobutyric acid on freshly isolated pyramidal neurons from the rat prefrontal cortex. *Neurosci Lett* 399:101-105, (2006).
- Song C. H., Xia J. X., Ye J. N., Chen X. W., Zhang C. Q., Gao E. Q., Hu Z. A., (2005).** Signaling pathways of hypocretin-1 actions on pyramidal neurons in the rat prefrontal cortex. *Neuroreport* 16 1529–1533.
- Sotiriou E., Papatheodoropoulos C., Angelatou F. (2005).** Differential expression of gamma-aminobutyric acid A receptor subunits in rat dorsal and ventral hippocampus. *J Neurosci Res* 82:690-700.

- Sotres-Bayon F., Cain C. K., LeDoux J. E. (2006).** Brain mechanisms of fear extinction: Historical perspectives on the contribution of prefrontal cortex. *Biol Psychiatry* 60:329–336.
- Sperk G., Furtinger S., Schwarzer C., Pirker S. (2004).** GABA and its receptors in epilepsy. *Adv Exp Med Biol* 548:92-103.
- Sperk G., Schwarzer C., Tsunashima K., Fuchs K., Sieghart W. (1997).** GABA<sub>A</sub> receptor subunits in the rat hippocampus. Immunocytochemical distribution of thirteen subunits. *Neuroscience* 80,987-1000.
- Spiegel K, Tasali E, Penev P, Van Cauter E.** Brief communication: Sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite. *Ann Intern Med* 141:846-850, (2004).
- Spinazzi R., Andreis P. G., Rossi G. P., Nussdorfer G. G., (2006).** Orexins in the regulation of the hypothalamic-pituitary-adrenal axis. *Pharmacol Rev.* 58: 46-57.
- Stein D. J. (2008).** Psychobiology of anxiety disorders and obsessive-compulsive spectrum disorder. *CNS Spectr* 13(Suppl 14):23-8.
- Steinberg R., Alonso R., Griebel G., Bert L., Jung M., Oury-Donat F., Poncelet M., Gueudet C., Desvignes C., Le Fur G., Soubrié P. (2001).** Selective blockade of neurokinin-2 receptors produces antidepressant-like effects associated with reduced corticotropin-releasing factor function. *J Pharmacol Exp Ther* 299,449–458.
- Stephenson FA.** Identification, molecular cloning, and characterization of a novel GABA<sub>A</sub> receptor-associated protein, GRIF-1. *J Biol Chem* 277:30079-30090, (2002).
- Storey K.B. (2001).** Turning down the fires of life: metabolic regulation of hibernation and estivation. In: *Molecular Mechanisms of Metabolic Arrest. Edited by Storey K.B. Oxford, UK. BIOS Scientific.*
- Strand F. L. (1999).** Tachykinins: substance P, neurokinin A, and neurokinin B. In: Stevens, C.F. (Ed.), *Neuropeptides: Regulators of Physiological Processes. The MIT Press Cambridge MA* 365–382.
- Strange B. A., Dolan R. J. (2004).** Beta-adrenergic modulation of emotional memory-evoked human amygdala and hippocampal responses. *Proc Natl Acad Sci USA* 101:11454–11458.
- Sun Y. G., Gu X. L., Lundeberg T., Yu L. C. (2003).** An antinociceptive role of galanin in the arcuate nucleus of hypothalamus in intact rats and rats with inflammation. *Pain* 106:143–50.
- Sutcliffe J. G., de Lecea L., (2000).** The hypocretins: excitatory neuromodulatory peptides for multiple homeostatic systems, including sleep and feeding. *J Neurosci Res* 62: 161–168.
- Sutcliffe J. R and de Lecea L., (2002).**The hypocretins: setting the arousal threshold *Nature Reviews Neurosci* 3, 339-349.
- Suzuki M., Beuckmann C. T., Shikata K., Ogura H., Sawai T. (2005).** Orexin-A (hypocretin-1) is possibly involved in generation of anxietylike behavior. *Brain Res* 1044:116–121.
- Swansn L. W., (2000).** Cerebral hemisphere regulation of motivated behaviour *Brain Res* 886: 113–164.

**Swanson G. T., Green T., Sakai R., Contractor A., Chew., Kamiya H., Heinemann S. F., (2002).** Differential activation of individual subunits in heteromeric Kainate receptors. *Neuron* 34:589-598.

**Swanson C. J., Blackburn T. P., Zhang X., Zheng K., Xu Z. Q., Hökfelt T., Wolinsky T. D., Konkel M. J., Chen H., Zhong H., Walker M. W., Craig D. A., Gerald C. P., Branchek T. A. (2005).** Anxiolytic- and antidepressant-like profiles of the galanin-3 receptor (Gal3) antagonists SNAP 37889 and SNAP 398299. *Proc Natl Acad Sci USA* 102,17489–17494.

**Swanson C. J., Bures M., Johnson M. P., Linden A. M., Monn J. A., Schoepp D. D. (2005).** Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. *Nat Rev Drug Discov* 4:131–144.

**Szabadi E. (2006).** Drugs for sleep disorders: mechanisms and therapeutic prospects. *Br J Clin Pharmacol* 61:761-766.

**Szinyei C., Heinbockel T., Montagne J., Pape H. C. (2000).** Putative cortical and thalamic inputs elicit convergent excitation in a population of GABAergic interneurons of the lateral amygdala. *J Neurosci* 20:8909-8915.

**Taheri S, Lin L, Austin D, Young T, Mignot E. (2004).** Short sleep duration is associated with reduced leptin, elevated ghrelin, and increased body mass index. *PLoS Med* 1:62.

**Taheri S, Sunter D, Dakin C, Moyes S, Seal L, Gardiner J, Rossi M, Ghatei Mand Bloom S. (2000).** Diurnal variation in orexin A immunoreactivity and prepro-orexin mRNA in the rat central nervous system. *Neurosci Lett* 279:109-112.

**Taheri S., Bloom S. (2001).** Orexins/hypocretins: waking up the scientific world. *Clin Endocrinol* 54:421-429.

**Totsune K., (2005).** Expression of orexin-A and orexin receptors in the kidney and the presence of orexin-A-like immunoreactivity in human urine. *Peptides*. 27: 871-877.

**Takai T., Takaya T., Nakano M., Akutsu H., Nakagawa T., Aimoto S., Nagai K. and Ikegami T., (2006).** Orexin-A is composed of a highly conserved C-terminal and a specific, hydrophilic N-terminal region, revealing the structural basis of specific recognition by the orexin-1 receptor *J Peptide Sci* 12, 443–454.

**Takakusaki K, Takahashi K, Saitoh K, Harada H, Okumura T, Kayama Y, Koyama Y.** Orexinergic projections to the midbrain mediate alternation of emotional behavioural states from locomotion to cataplexy. *J Physiol* 568:1003-1020, (2005).

**Takamori, K., Yoshida, S., Okuyama S., (2001).** Repeated treatment with imipramine, fluvoxamine and tranylcypromine decreases the number of escape failures by activating dopaminergic systems in a rat learned helplessness test. *Life Sciences* 69 (16),1919–1926.

**Tanaka M, Yoshida M, Emoto H, Ishii H. (2000).** Noradrenaline systems in the hypothalamus, amygdala and locus coeruleus are involved in the provocation of anxiety: basic studies. *Eur J Pharmacol* 405:397-406.

- Tannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M, Cornford M, Siegel JM. (2000).** Reduced number of hypocretin neurons in human narcolepsy. *Neuron* 27:469-474,
- Taylor MM and Samson WK. (2003).** The other side of the orexins: endocrine and metabolic actions. *Am J Physiol Endocrinol Metab* 284:E13-E17.
- Telegdy G., Adamik A., (2002).** The action of orexin A on passive avoidance learning. Involvement of transmitters. *Regul Pept*; 104:105–10.
- Teske J. A., Levine A. S., Kuskowski M., Levine J. A., Kotz C. M. (2006).** Elevated hypothalamic orexin signaling, sensitivity to orexin A and spontaneous physical activity in obesity resistant rats. *Am J Physiol Regul Integr Comp Physiol* 291(4):R889-99.
- Thakkar MM, Ramesh V, Strecker RE, McCarley RW. (2001).** Microdialysis perfusion of orexin-A in the basal forebrain increases wakefulness in freely behaving rats. *Arch Ital Biol* 139: 313-328.
- Thannickal T. C., Moore R. Y., Nienhuis R., Ramanathan L, Gulyani S, Aldrich M., Cornford M., Siegel JM., (2000).** Reduced number of hypocretin neurons in human narcolepsy. *Neuron.* 27:469–474.
- Thoeringer C. K., Ripke S., Unschuld P. G., Lucae S., Ising M., Bettecken T., Uhr M., Keck M. E., Mueller-Myhsok B., Holsboer F., Binder E. B., Erhardt A. (2008).** The GABA transporter 1 (SLC6A1): a novel candidate gene for anxiety disorders. *J Neural Transm* 116(6):649-57.
- Thomas M, Sing H, Belenky G, Holcomb H, Mayberg H, Dannals R, Wagner H, Thorne D, Popp K, Rowland L, Welsh A, Balwinski S, Redmond D. (2000).** Neural basis of alertness and cognitive performance impairments during sleepiness. I. Effects of 24 h of sleep deprivation on waking human regional brain activity. *J Sleep Res* 9:335-352.
- Thorpe A. J., Doanee D. F., Sweetd D. C., Beverlye J. L., Kotz C. M. (2006).** Orexin A in the rostromedial hypothalamic area induces feeding by modulating GABAergic transmission. *Brain Res* 1125:60-66.
- Thorpe A. J., Mullett M. A., Wang C., Kotz C. M. (2003).** Peptides that regulate food intake: regional metabolic, and circadian specificity of lateral hypothalamic orexin A feeding stimulation. *Am J Physiol Regul Integr Comp Physiol* 284:R1409-R1417.
- Timpl P., Spanagel R., Sillaber I., Kresse A., Reul J. M. H. M., Stalla G. K., Blanquet, V., Steckler T., Holsboer F., Wurst W. (1998).** Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. *Nat Genet* 19,162– 166.
- Tominaga M., Yagami K., Sugiyama F., Goto K., Yanagisawa M., Sakurai T., (2003).** Hypothalamic orexin neurons regulate arousal according to energy balance in mice. *Neuron* 38: 701–713.
- Torrealba F., Yanagisawa M., Saper C. B., (2003).** Colocalization of orexin a and glutamate immunoreactivity in axon terminals in the tuberomammillary nucleus in rats. *Neuroscience* 119: 1033–1044.
- Tononi G, Cirelli C.** Sleep function and synaptic homeostasis. *Sleep med Rev* 10:49-62, (2006).

- Torrealba F, Yanagisawa M, Saper CB.** Colocalization of orexin a and glutamate immunoreactivity in axon terminals in the tuberomammillary nucleus in rats. *Neurosci* 119:1033-1044, (2003).
- Torta R., Monaco F. (2002).** Atypical antipsychotics and serotonergic antidepressants in patients with epilepsy: pharmacodynamic considerations. *Epilepsia* 43 Suppl 2:8-13.
- Toshinai K., Date Y., Murakami N., Shimada M., Mondal M. S., Shimbara T., Guan J. L., Wang Q. P., Funahashi H., Sakurai T., Shioda S., Matsukura S., Kangawa K., Nakazato M., (2003).** Ghrelin-induced food intake is mediated via the orexin pathway. *Endocrinology* 144: 1506–1512.
- Trigo F. F., Marty A., Stell B. M. (2008).** Axonal GABA<sub>A</sub> receptors. *Eur J of Neurosci* 28:841-848.
- Tschenett A., Singewald N., Carli M., Balducci C., Salchner P., Vezzani A., Herzog H., Sperk G. (2003).** Reduced anxiety and improved stress coping ability in mice lacking NPY-Y2 receptors. *Eur J Neurosci* 18,143–148.
- Tseng K. Y., O'Donnell P., (2005).** Dopamine–glutamate interactions controlling prefrontal cortical pyramidal cell excitability involve multiple signalling mechanisms, *J. Neurosci.* 24 5131–5139.
- Tsujino N., Yamanaka A., Ichiki K., Muraki Y., Kilduff TS., Yagami K., Takahashi S., Goto K., Sakurai T., (2005).** Cholecystokinin activates orexin/ hypocretin neurons through the cholecystokinin A receptor. *J. Neurosci* 25:7459-7469.
- Tsvetkov E., Carlezon W. . A., Benes F. M., Kandel E. R and Bolshakov V. Y., (2002).** Fear conditioning occludes LTP-induced presynaptic enhancement of synaptic transmission in the cortical pathway to the lateral amygdala. *Neuron* 34: 289–300.
- Unschuld P. G., Ising M., Erhardt A., Lucae S., Kohli M., Kloiber S., Salyakina D., Thoeringer C. K., Kern N., Lieb R., Uhr M., Binder E. B., Müller-Myhsok B., Holsboer F., Keck M. E. (2008).** Polymorphisms in the galanin gene are associated with symptom-severity in female patients suffering from panic disorder. *J Affect Disord* 105,177–184.
- Van den Pol A. N., Gao X. B., Obrietan K. Kilduff T. S., Belousov A. B., (1998).** Presynaptic and postsynaptic actions and modulation of neuroendocrine neurons by a new hypothalamic peptide, hypocretin/orexin. *J Neurosci* 18:7962-7971.
- Van den Pol T. M., Nolan M. F., Lee K., Richardson P. J., Buijs R. M., Davies C.H., Spanswick D. (2003).** Orexins induce increased excitability and synchronisation of rat sympathetic preganglionic neurones. *J Physiol* 549:809–821.
- Van Pett K., Viau V., Bittencourt J. C., Chan R. K., Li H. Y., Arias C., Prins G. S., Perrin M., Vale W., Sawchenko P. E. (2000).** Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. *J Comp Neurol* 428,191–212.
- Van Pett K., Viau V., Bittencourt J. C., Chan R. K., Li H. Y., Arias C., Prins G. S., Perrin M., Vertes R. P. (2004).** Differential projections of the infralimbic and prelimbic cortex in the rat. *Synapse* 51:32–58.

- Van den Top M., Lee K., Whyment A. D., Blanks A. M., Spanswick D., (2004).** Orexigen-sensitive NPY/AgRP pacemaker neurons in the hypothalamic arcuate nucleus. *Nat Neurosci* 7: 493–494.
- Van Economo C., (1999).** Sleep as a problem of localization. *J. Nerv. Ment. Dis.* 71:249–269.
- Varas M. M., Pèrez M. F., Ramí rez O. A., de Barioglio S. R., (2003).** Increased susceptibility to LTP generation and changes in NMDA-NR1 and NR2B subunits mRNA expression in rat hippocampus after MCH administration. *Peptides*; 24:1403–11.
- Vazdarjanova A. and Mcgaugh J. L., (1999).** Basolateral amygdala is involved in modulating consolidation of memory for classical fear conditioning. *J Neurosci* 19: 6615–6622.
- Vittoz N. M., Berridge C. W. (2006).** Hypocretin/orexin selectively increases dopamine efflux within the prefrontal cortex: involvement of the ventral tegmental area. *Neuropsychopharmacology* 31:384–395.
- Viveros M. P., Marco E. M., File S. E. (2005).** Endocannabinoid system and stress and anxiety responses. *Pharmacol Biochem Behav* 81(2):331-342.
- Volkoff H. (2006).** The role of neuropeptide Y, orexins, cocaine and amphetamine-related transcript, cholecystokinin, amylin and leptin in the regulation of feeding in fish. *Comp Biochem Physiol* 144:325-331.
- Voisin T., Rouet-Benzineb P., Reuter N., Laburthe M., (2003).** Orexins and their receptors: structural aspects and role in peripheral tissues. *Cell. Mol. Life Sci.* 60: 72-87.
- Von der Ohe C. G., Darian-Smith C., Garner C. C., Heller H. C., (2006).** Ubiquitous and temperature-dependent neural plasticity in hibernators. *J Neurosci* 26:10590-10598.
- Von der Ohe C. G., Garner C. C., Darian-Smith C., Heller H. C., (2007).** Synaptic protein dynamics in hibernation. *J Neurosci* 27:84-92.
- Wafford K. A. (2005).** GABA<sub>A</sub> receptor subtypes: any clues to the mechanism of benzodiazepine dependence? *Curr Opin Pharmacol* 5:47-52.
- Waleh N. S., Apte-Deshpande A., Terao A., Ding J. and Kilduff T. S., (2001).** Modulation of the promoter region of preprohypocretin by alpha-interferon. *Gene* 262, 123–128.
- Walker D. L., Ressler K. J., Lu K. T. Davis M. (2002).** Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear potentiated startle in rats. *The Journal of Neuroscience* 22:2343–2351.
- Walker M. P., Stickgold R., (2004).** Sleep-dependent learning and memory consolidation. *Neuron* 44:121-133.
- Walling S. G., Nutt D. J., Lalies M. D., Harley C. W., (2004).** Orexin-A infusion in the locus ceruleus triggers norepinephrine (NE) release and NE-induced long-term potentiation in the dentate gyrus. *J. Neurosci.* 24, 7421–7426.



- Wang J. B., Murata T., Narita K., Honda K., Higuchi T., (2003).** Variation in the expression of orexin and orexin receptors in the rat hypothalamus during the estrous cycle, pregnancy, parturition and lactation. *Endocrine*. 22: 127-134.
- Wayner M. J., Armstrong D. L., Phelix C. F., Oomura Y. (2004).** Orexin-A (hypocretin-1) and leptin enhance LTP in the dentate gyrus of rats in vivo. *Peptides* 25,991–996.
- Wei W., Zhang N., Peng Z., Houser C. R., Mody I. (2003).** Perisynaptic localization of  $\delta$  subunit containing GABA<sub>A</sub> receptors and their activation by GABA spillover in the mouse dentate gyrus. *J Neurosci* 23:10650-10661.
- Weiss J. M., Boss-Williams K. A., Moore J. P., Demetrikopoulos M. K., Ritchie J. C., West C. H. (2005).** Testing the hypothesis that locus coeruleus hyperactivity produces depression-related changes via galanin. *Neuropeptides* 39,281.
- Whalen M. J., Carlos T. M., Dixon C. E., Robichaud P., Clark R. S., Marion D. W., Kochanek P. M., (2000).** Effect of neutropenia and granulocyte colony stimulating factor induced neutrophilia on blood-brain permeability and brain edema after traumatic brain injury un rats. *Crit Care Med* 28:3710-3717.
- White C. L., Ishii Y., Mendoza T. (2005).** Effect of a selective OX1R antagonist on food intake and body weight in two strains of rats that differin susceptibility to dietary-induced obesity. *Peptides* 26:2331-2338.
- White T., Cullen K., RohrerL. M., Karatekin C., Luciana M., Schmidt M., Hongwanishkul D., Kumra S., Schulz S. C., Lim K. O. (2008).** Limbic Structures and Networks in Children and Adolescents With Schizophrenia. *Schizophrenia Bulletin* 34:18–29.
- Whiting PJ.** The GABAA receptor gene family: new opportunities for drug development. *Curr Opin Drug Disc Dev* 6:648-657, (2003).
- Wilensky A. E., Schafe G. E. and Ledoux J. E., (1999).** Functional inactivation of the amygdala before but not after auditory fear conditioning prevents memory formation. *J Neurosci* 19: RC48.
- Williams H. S. C., Richardson J. A., Kozlowski G. P., Wilson S., Arch J. R., Sakurai T., Amemiya A., Ishii M., Matsuzaki I., Chemelli R. M., Tanaka Buckingham R. E., Haynes A. C., Carr S. A., Annan R. S., McNulty D. E., Liu W. S., Terrett J. A., Elshourbagy N. A., Bergsma D. J., Yanagisawa M., (1998).** Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. *Cell* 92: 573–585.
- Wirkner K., KrauseT., Koles L., Thummler S., Al-Khrasani M., Illes P., (2004).** D1 but not D2 dopamine receptors or adrenoceptors mediate dopamine-induced potentiation of *N*-methyl-d-aspartate currents in the rat prefrontal cortex, *Neurosci. Lett.* 372 89–93.
- Wisor J. P., Nishino S., Sora I., Uhl G. H., Mignot E., Edgar DM., (2001).** Dopaminergic role in stimulant-induced wakefulness. *J. Neurosci.* 21:1787–1794.

- Xia J., Chen X., Song C., Ye J., Yu Z., Hu Z., (2005).** Postsynaptic excitation of prefrontal cortical pyramidal neurons by hypocretin-1/orexin a through the inhibition of potassium currents. *J. Neurosci. Res.* 82 729–736.
- Yagami K, Goto K, Yanagisawa M, Sakurai T.** Genetic ablation of orexin neurons in miceresults in narcolepsy, hypophagia, and obesity. *Neuron* 30:345-354, (2001).
- Yamamoto Y, Ueta Y, Serino R, Nomura M, Shibuya I, Yamashita H.** Effects of food restriction on the hypothalamic prepro-orexin gene expression in genetically obese mice. *Brain Res Bull* 51:515-21, (2000).
- Yamanaka A., Muraki Y., Tsujino N., Goto K., Sakurai T. (2003).** Regulation of orexin neurons by the monoaminergic and cholinergic systems. *Biochem Biophys Res Commun* 303 (1)120–129.
- Yamanaka A, Beuckmann CT, Willie JT, Hara J, Tsujino N, Mieda M, Tominaga M, Yagami K, Sugiyama F, Goto K, Yanagisawa M, Sakurai T.** Hypothalamic orexin neurons regulate arousal according to energy balance in mice. *Neuron* 38:701-713, (2003).
- Yamanaka A., Tsujino N., Funahashi H., Honda K., Guan J. L., Wang Q. P., Tominaga M., Goto K., Shioda S., Sakurai T. (2002).** Orexins activate histaminergic neurons via the orexin 2 receptor. *Biochem. Biophys. Res. Commun* 290(4)1237–1245
- Yamanaka A, Kunii K, Tsujino N, Goto K, Sakurai T. (2000).** Orexin-induced food intake involves neuropeptide Y pathway. *Brain Res* 859:404-409.
- Yamasaki H., LaBar K. S., McCarthy G., (2002).** Dissociable prefrontal brain systems for attention and emotion, *Proc. Natl. Acad. Sci. U.S.A.* 99 11447–11451.
- Yee B. K., Hauser J., Dolgov V. V., Keist R., Möhler H., Rudolph U., Feldon J. (2004).** GABA<sub>A</sub> receptors containing the  $\alpha 5$  subunit mediate the trace effect in aversive and appetitive conditioning and extinction of conditioned fear. *Eur J Neurosci* 20:1928-1936.
- Yehuda R., Brand S., Yang R. K. (2006).** Plasma neuropeptide Y concentrations in combat exposed veterans: relationship to trauma exposure, recovery from PTSD, and coping. *Biol Psychiatry* 59,660–663.
- Yoshida K., McCormack S., Espana RA., Crocker A. and Scammell TE., (2006).** Afferents to the orexin neurons of the rat brain. *J. Comp. Neurol.* 494:845–861.
- Yoshida Y, Fujiki N, Nakajima T, Ripley, Matsumura H, Yoneda H, Mignot E, Nishino S.** Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities. *Eur J Neurosci* 14:1075-1081, (2001).
- Yoshimichi G., Yoshimatsu H., Masaki T., Sakata T.( 2001).** Orexin-A regulates body temperature in coordination with arousal status. *Exp Biol Med* 226(5):468-76.
- Yuen E. Y., Jiang Q., Chen P., Gu Z., Feng J., Yan Z., (2005).** Serotonin 5-HT<sub>1A</sub> receptors regulate NMDA receptor channels through a microtubule-dependent mechanism, *J. Neurosci.* 25 5488–5501.

- Zeitler J. M., Buckmaster C. L., Parker K. J., Hauck C. M., Lyons D. M., Mignot E., (2003).** Circadian and homeostatic regulation of hypocretin in a primate model: implications for the consolidation of wakefulness. *J Neurosci* 23:3555-3560.
- Zhang S., Blache D., Vercoe P. E., Adam C. L., Blackberry M. A., Findlay P. A., Eidne K. A., Martin G. B., (2005).** Expression of orexin receptors in the brain and peripheral tissues of the male sheep. *Reg. Pept.* 124: 81-87.
- Zhang LL, Chen L, Xue Y, Yung WH.** Modulation of synaptic GABAA receptor function by zolpidem in substantia nigra pars reticulata. *Acta Pharmacol Sin* 29:161-168, (2008).
- Zhang N., Wei W., Mody I., Houser C. R. (2007).** Altered localization of GABAA receptor subunits on dentate granule cell dendrites influences tonic and phasic inhibition in a mouse model of epilepsy. *J Neurosci* 27:7520–7531.
- Zhong P., Gu Z., Wang X., Jiang H., Feng J., Yan Z., (2003).** Impaired modulation of GABAergic transmission by muscarinic receptors in a mouse transgenic model of Alzheimer's disease, *J. Biol. Chem.* 278 26888–26896.
- Zhu Y., Miwa Y., Yamanaka A., Yada T., Shibahara M., Abe Y., (2003).** Orexin receptor type 1 couples exclusively to pertussis toxin- insensitive G-protein, while orexin receptor type 2 couples to both pertussis toxin-sensitive and-insensitive G-proteins. *J. Pharmacol. Sci.* 92: 259-266.
- Zhu Y, Yamanaka A, Kunii K, Tsujino N, Goto K , Sakurai T.** Orexin-mediated feeding behavior involves both leptin-sensitive and insensitive pathways. *Physiol Behav* 77:251-257, (2002).
- Ziolkowska A., Spinazzi R., Albertin G. Nowak M., Malendowicz L. K., Tortorella C., Nussdorfer G. G. (2005).** Orexins stimulate glucocorticoid secretion from cultured rat and human adrenocortical cells, exclusively acting via the OX1 receptor. *J Steroid Biochem Mol Biol* 96:423-429.
- Zwanzger P., Deckert J. (2007).** Anxiety disorders. Causes, clinical picture and treatment. *Nervenarzt* 78:349-59.